Document:

<PAGE>

                                                                   EXHIBIT 10.39

                                                                  EXECUTION COPY

                          SECURITIES PURCHASE AGREEMENT

         This Securities Purchase Agreement (this "AGREEMENT") is dated as of
September 24, 2003 by and between Lynx Therapeutics, Inc., a Delaware
corporation (the "COMPANY"), and each purchaser identified on the signature
pages hereto (each, a "PURCHASER" and collectively, the "PURCHASERS").

         WHEREAS, subject to the terms and conditions set forth in this
Agreement and pursuant to Section 4(2) of the Securities Act of 1933, as
amended, the Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the Company,
certain securities of the Company as more fully described in this Agreement.

         NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in
this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each of the
Purchasers agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

         1.1      Definitions. In addition to the terms defined elsewhere in
this Agreement, the following terms have the meanings indicated:

                  "AFFILIATE" means any Person that, directly or indirectly
         through one or more intermediaries, controls or is controlled by or is
         under common control with a Person, as such terms are used in and
         construed under Rule 144.

                  "BANKRUPTCY EVENT" means any of the following events: (a) the
         Company or any Subsidiary commences a case or other proceeding under
         any bankruptcy, reorganization, arrangement, adjustment of debt, relief
         of debtors, dissolution, insolvency or liquidation or similar law of
         any jurisdiction relating to the Company or any Subsidiary thereof; (b)
         there is commenced against the Company or any Subsidiary any such case
         or proceeding that is not dismissed within 60 days after commencement;
         (c) the Company or any Subsidiary is adjudicated insolvent or bankrupt
         or any order of relief or other order approving any such case or
         proceeding is entered; (d) the Company or any Subsidiary suffers any
         appointment of any custodian or the like for it or any substantial part
         of its property that is not discharged or stayed within 60 days; (e)
         the Company or any Subsidiary makes a general assignment for the
         benefit of creditors; (f) the Company or any Subsidiary fails to pay,
         or states that it is unable to pay or is unable to pay, its debts
         generally as they become due; (g) the Company or any Subsidiary calls a
         meeting of its creditors with a view to arranging a composition,
         adjustment or restructuring of its debts; or (h) the Company or any
         Subsidiary, by any act or failure to act, expressly indicates its
         consent to, approval of or acquiescence in any of the foregoing or
         takes any corporate or other action for the purpose of effecting any of
         the foregoing.

<PAGE>

                  "BUSINESS DAY" means any day other than Saturday, Sunday or
         other day on which commercial banks in The City of New York are
         authorized or required by law to remain closed.

                   "CHANGE OF CONTROL" means the consummation of a "Rule 13e-3
         transaction" as defined in Rule 13e-3 under the Exchange Act with
         respect to the Company or the execution by the Company or its
         controlling stockholders of an agreement providing for or reasonably
         likely to result in the foregoing event.

                  "CLOSING" means the closing of the purchase and sale of the
         Shares and the Warrants pursuant to Section 2.1.

                  "CLOSING DATE" means the date of the Closing.

                  "CLOSING PRICE" means, for any date, the price determined by
         the first of the following clauses that applies: (a) if the Common
         Stock is then listed or quoted on an Eligible Market or any other
         national securities exchange, the closing bid price per share of the
         Common Stock for such date (or the nearest preceding date) on the
         primary Eligible Market or exchange on which the Common Stock is then
         listed or quoted; (b) if prices for the Common Stock are then quoted on
         the OTC Bulletin Board, the closing bid price per share of the Common
         Stock for such date (or the nearest preceding date) so quoted; (c) if
         prices for the Common Stock are then reported in the "Pink Sheets"
         published by the National Quotation Bureau Incorporated (or a similar
         organization or agency succeeding to its functions of reporting
         prices), the most recent closing bid price per share of the Common
         Stock so reported; or (d) in all other cases, the fair market value of
         a share of Common Stock as determined by an independent appraiser
         selected in good faith by a majority-in-interest of the Purchasers.

                  "COMMISSION" means the Securities and Exchange Commission.

                  "COMMON STOCK" means the common stock of the Company, par
         value $0.01 per share.

                  "COMMON STOCK EQUIVALENTS" means, collectively, Options and
         Convertible Securities.

                  "COMPANY COUNSEL" means Cooley Godward LLP.

                   "CONVERTIBLE SECURITIES" means any stock or securities (other
         than Options) convertible into or exercisable or exchangeable for
         Common Stock.

                   "EFFECTIVE DATE" means the date that the Registration
         Statement is first declared effective by the Commission.

                  "ELIGIBLE MARKET" means any of the New York Stock Exchange,
         the American Stock Exchange, the NASDAQ National Market or the NASDAQ
         Small Cap Market.

                  "EXCHANGE ACT" means the Securities Exchange Act of 1934, as
         amended.

                                       2

<PAGE>

                  "EXCLUDED STOCK" means the issuance of Common Stock (A) upon
         exercise or conversion of any options or other securities described in
         Schedule 3.1(f) (provided that such exercise or conversion occurs in
         accordance with the terms thereof, without amendment or modification,
         and that the applicable exercise or conversion price or ratio is
         described in such schedule), (B) in connection with any grant of
         options, warrants or the issuance of additional securities to
         employees, officers, directors or consultants of the Company pursuant
         to a stock option plan or stock purchase plan duly adopted by the
         Company's board of directors or in respect of the issuance of Common
         Stock upon exercise of any such options, (C) pursuant to a bona fide
         firm commitment underwritten public offering with a nationally
         recognized underwriter (excluding any equity line) in an aggregate
         offering amount greater than $20,000,000, or (D) in connection with a
         bona fide joint venture or development agreement or strategic
         partnership, the primary purpose of which is not to raise equity
         capital.

                  "FILING DATE" means October 24, 2003.

                  "LIEN" means any lien, charge, claim, security interest,
         encumbrance, right of first refusal or other restriction.

                  "LOSSES" means any and all losses, claims, damages,
         liabilities, settlement costs and expenses, including, without
         limitation, costs of preparation and reasonable attorneys' fees.

                  "OPTIONS" means any rights, warrants or options to subscribe
         for or purchase Common Stock or Convertible Securities.

                  "PERSON" means any individual or corporation, partnership,
         trust, incorporated or unincorporated association, joint venture,
         limited liability company, joint stock company, government (or an
         agency or subdivision thereof) or any court or other federal, state,
         local or other governmental authority or other entity of any kind.

                  "PROCEEDING" means an action, claim, suit, investigation or
         proceeding (including, without limitation, an investigation or partial
         proceeding, such as a deposition), whether commenced or threatened.

                  "PROSPECTUS" means the prospectus included in the Registration
         Statement (including, without limitation, a prospectus that includes
         any information previously omitted from a prospectus filed as part of
         an effective registration statement in reliance upon Rule 430A
         promulgated under the Securities Act), as amended or supplemented by
         any prospectus supplement, with respect to the terms of the offering of
         any portion of the Registrable Securities covered by the Registration
         Statement, and all other amendments and supplements to the Prospectus,
         including post-effective amendments, and all material incorporated by
         reference or deemed to be incorporated by reference in such Prospectus.

                   "REGISTRABLE SECURITIES" means any Common Stock (including
         Underlying Shares) issued or issuable pursuant to the Transaction
         Documents, together with any securities issued or issuable upon any
         stock split, dividend or other distribution, recapitalization or
         similar event with respect to the foregoing.

                                       3

<PAGE>

                  "REGISTRATION STATEMENT" means each registration statement
         required to be filed under Article VI, including (in each case) the
         Prospectus, amendments and supplements to such registration statement
         or Prospectus, including pre- and post-effective amendments, all
         exhibits thereto, and all material incorporated by reference or deemed
         to be incorporated by reference in such registration statement.

                  "REQUIRED EFFECTIVENESS DATE" means December 23, 2003.

                  "RULE 144," "RULE 415," and "RULE 424" means Rule 144, Rule
         415 and Rule 424, respectively, promulgated by the Commission pursuant
         to the Securities Act, as such Rules may be amended from time to time,
         or any similar rule or regulation hereafter adopted by the Commission
         having substantially the same effect as such Rule.

                  "SECURITIES" means the Shares, the Warrants and the Underlying
         Shares.

                  "SECURITIES ACT" means the Securities Act of 1933, as amended.

                  "SHARES" means an aggregate of 744,000 shares of Common Stock,
         which are being issued and sold to the Purchasers at the Closing.

                  "SUBSIDIARY" means any Person in which the Company, directly
         or indirectly, owns a majority of the capital stock or holds an equity
         or similar majority interest that are required to be listed in Schedule
         3.1(a).

                  "TRADING DAY" means (a) any day on which the Common Stock is
         listed or quoted and traded on its primary Trading Market, (b) if the
         Common Stock is not then listed or quoted and traded on any Eligible
         Market, then a day on which trading occurs on the NASDAQ Small Cap
         Market (or any successor thereto), or (c) if trading does not occur on
         the NASDAQ Small Cap Market (or any successor thereto), any Business
         Day.

                  "TRADING MARKET" means the NASDAQ Small Cap Market or any
         other Eligible Market on which the Common Stock is then listed or
         quoted.

                  "TRANSACTION DOCUMENTS" means this Agreement, the Warrants,
         the Transfer Agent Instructions and any other documents or agreements
         executed in connection with the transactions contemplated hereunder.

                  "TRANSFER AGENT" means EquiServe Trust Company, N.A. or any
         other transfer agent selected by the Company.

                  "TRANSFER AGENT INSTRUCTIONS" means the Irrevocable Transfer
         Agent Instructions, in the form of Exhibit D, executed by the Company
         and delivered to and acknowledged in writing by the Transfer Agent.

                  "UNDERLYING SHARES" means the shares of Common Stock issuable
         upon exercise of the Warrants and any securities issued in exchange for
         or in respect of such shares.

                                       4

<PAGE>

                  "WARRANTS" means, collectively, the Common Stock purchase
         warrants issued and sold under this Agreement, in the form of Exhibit
         A, and any warrants issued upon exercise of such warrants.

                                   ARTICLE II
                                PURCHASE AND SALE

         2.1      Closing. Subject to the terms and conditions set forth in this
Agreement, at the Closing the Company shall issue and sell to each Purchaser,
and each Purchaser shall, severally and not jointly, purchase from the Company,
such number of Shares and a Warrant to purchase such number of Underlying
Shares, each as indicated below such Purchaser's name on the signature page of
this Agreement, for an aggregate purchase price for such Purchaser as indicated
below such Purchaser's name on the signature page of this Agreement. The Closing
shall take place at the offices of Proskauer Rose LLP immediately following the
execution hereof, or at such other location or time as the parties may agree.

         2.2      Closing Deliveries.

                      (a)      At the Closing, the Company shall deliver or
    cause to be delivered to each Purchaser the following:

                           (i)      one or more stock certificates, free and
         clear of all restrictive and other legends (except as expressly
         provided in Section 4.1(b) hereof), evidencing the number of Shares
         indicated below such Purchaser's name on the signature page of this
         Agreement, registered in the name of such Purchaser;

                           (ii)     a Warrant, registered in the name of such
         Purchaser, pursuant to which such Purchaser shall have the right to
         acquire the number of Underlying Shares indicated below such
         Purchaser's name on the signature page of this Agreement, on the terms
         set forth therein;

                           (iii)    a legal opinion of Company Counsel, in the
         form of Exhibit B, executed by such counsel and delivered to the
         Purchasers; and

                           (iv)     duly executed Transfer Agent Instructions
         acknowledged by the Transfer Agent.

                      (b)      At the Closing, each Purchaser shall deliver or
    cause to be delivered to the Company the purchase price indicated below such
    Purchaser's name on the signature page of this Agreement, in United States
    dollars and in immediately available funds, by wire transfer to an account
    designated in writing by the Company for such purpose.

                      (c)      Notwithstanding anything to the contrary in this
    Section 2.2, in the event that the Company cannot deliver all of the items
    set forth in Sections 2.2(a) above, each Purchaser shall instead deliver the
    purchase price set forth in Section 2.2(b) (the "ESCROW FUNDS") to the
    Company Counsel, to be held by the Company Counsel in escrow on behalf of
    such Purchaser. Upon confirmation from all the Purchasers of receipt by the
    Purchasers of all the items set forth in Sections 2(a) above (which may be
    in writing or via email), the

                                       5

<PAGE>

    Company Counsel shall release the Escrow Funds to the Company. In the event
    all of the items set forth in Sections 2(a) are not delivered to a Purchaser
    on or prior to September 26, 2003, the Company Counsel shall immediately
    return the Escrow Funds to a Purchaser upon the request of such Purchaser.
    The Company Counsel hereby acknowledges and agrees to act as escrow agent in
    accordance with this Section 2(c). The Company Counsel (i) shall be entitled
    to rely on any written or email communication received from a Purchaser and
    (ii) shall not be liable for any acts or omissions of any kind any unless
    caused by its own gross negligence or willful misconduct.

                                  ARTICLE III
                         REPRESENTATIONS AND WARRANTIES

         3.1      Representations and Warranties of the Company. The Company
hereby represents and warrants to each of the Purchasers as follows:

                      (a)      Subsidiaries. The Company has no direct or
    indirect Subsidiaries other than those listed in Schedule 3.1(a). Except as
    disclosed in Schedule 3.1(a), the Company owns, directly or indirectly, all
    of the capital stock or comparable equity interests of each Subsidiary free
    and clear of any Lien, and all the issued and outstanding shares of capital
    stock or comparable equity interests of each Subsidiary are validly issued
    and are fully paid, non-assessable and free of preemptive and similar
    rights.

                      (b)      Organization and Qualification. Each of the
    Company and the Subsidiaries is an entity duly organized, validly existing
    and in good standing under the laws of the jurisdiction of its incorporation
    or organization (as applicable), with the requisite power and authority to
    own and use its properties and assets and to carry on its business as
    currently conducted. Neither the Company nor any Subsidiary is in violation
    of any of the provisions of its respective certificate or articles of
    incorporation, bylaws or other organizational or charter documents. Each of
    the Company and the Subsidiaries is duly qualified to do business and is in
    good standing as a foreign corporation or other entity in each jurisdiction
    in which the nature of the business conducted or property owned by it makes
    such qualification necessary, except where the failure to be so qualified or
    in good standing, as the case may be, could not, individually or in the
    aggregate, (i) adversely affect the legality, validity or enforceability of
    any Transaction Document, (ii) have or result in a material adverse effect
    on the results of operations, assets, prospects, business or condition
    (financial or otherwise) of the Company and the Subsidiaries, taken as a
    whole, or (iii) adversely impair the Company's ability to perform fully on a
    timely basis its obligations under any of the Transaction Documents (any of
    (i), (ii) or (iii), a "MATERIAL ADVERSE EFFECT").

                      (c)      Authorization; Enforcement. The Company has the
    requisite corporate power and authority to enter into and to consummate the
    transactions contemplated by each of the Transaction Documents and otherwise
    to carry out its obligations hereunder and thereunder. The execution and
    delivery of each of the Transaction Documents by the Company and the
    consummation by it of the transactions contemplated hereby and thereby have
    been duly authorized by all necessary action on the part of the Company and
    no further consent or action is required by the Company, its Board of
    Directors or its stockholders. Each of the Transaction Documents has been
    (or upon delivery will be) duly executed by the

                                       6

<PAGE>

    Company and is, or when delivered in accordance with the terms hereof, will
    constitute, the valid and binding obligation of the Company enforceable
    against the Company in accordance with its terms.

                      (d)      No Conflicts. The execution, delivery and
    performance of the Transaction Documents by the Company and the consummation
    by the Company of the transactions contemplated hereby and thereby do not
    and will not (i) conflict with or violate any provision of the Company's or
    any Subsidiary's certificate or articles of incorporation, bylaws or other
    organizational or charter documents, (ii) conflict with, or constitute a
    default (or an event that with notice or lapse of time or both would become
    a default) under, or give to others any rights of termination, amendment,
    acceleration or cancellation (with or without notice, lapse of time or both)
    of, any agreement, credit facility, debt or other instrument (evidencing a
    Company or Subsidiary debt or otherwise) or other understanding to which the
    Company or any Subsidiary is a party or by which any property or asset of
    the Company or any Subsidiary is bound or affected, except to the extent
    that such conflict, default or termination right could not reasonably be
    expected to have a Material Adverse Effect, or (iii) result in a violation
    of any law, rule, regulation, order, judgment, injunction, decree or other
    restriction of any court or governmental authority to which the Company or a
    Subsidiary is subject (including federal and state securities laws and
    regulations and the rules and regulations of any self-regulatory
    organization to which the Company or its securities are subject), or by
    which any property or asset of the Company or a Subsidiary is bound or
    affected.

                      (e)      Issuance of the Securities. The Securities
    (including the Underlying Shares) are duly authorized and, when issued and
    paid for in accordance with the Transaction Documents, will be duly and
    validly issued, fully paid and nonassessable, free and clear of all Liens
    and shall not be subject to preemptive rights or similar rights of
    stockholders. The Company has reserved from its duly authorized capital
    stock the maximum number of shares of Common Stock issuable upon exercise of
    the Warrants.

                      (f)      Capitalization. The number of shares and type of
    all authorized, issued and outstanding capital stock, options and other
    securities of the Company (whether or not presently convertible into or
    exercisable or exchangeable for shares of capital stock of the Company) is
    set forth in Schedule 3.1(f). All outstanding shares of capital stock are
    duly authorized, validly issued, fully paid and nonassessable and have been
    issued in compliance with all applicable securities laws. Except as a result
    of the sale of the Warrants and as disclosed in Schedule 3.1(f), there are
    no outstanding options, warrants, script rights to subscribe to, calls or
    commitments of any character whatsoever relating to, or securities, rights
    or obligations convertible into or exercisable or exchangeable for, or
    giving any Person any right to subscribe for or acquire, any shares of
    Common Stock, or contracts, commitments, understandings or arrangements by
    which the Company or any Subsidiary is or may become bound to issue
    additional shares of Common Stock, or securities or rights convertible or
    exchangeable into shares of Common Stock. There are no anti-dilution or
    price adjustment provisions contained in any security issued by the Company
    (or in any agreement providing rights to security holders) and the issue and
    sale of the Securities (including the Underlying Shares) will not obligate
    the Company to issue shares of Common Stock or other securities to any
    Person (other than the Purchasers) and will not result in a right of any
    holder

                                       7

<PAGE>

    of Company securities to adjust the exercise, conversion, exchange or reset
    price under such securities. To the knowledge of the Company, except as
    specifically disclosed in Schedule 3.1(f), no Person or group of related
    Persons beneficially owns (as determined pursuant to Rule 13d-3 under the
    Exchange Act), or has the right to acquire, by agreement with or by
    obligation binding upon the Company, beneficial ownership of in excess of 5%
    of the outstanding Common Stock, ignoring for such purposes any limitation
    on the number of shares of Common Stock that may be owned at any single
    time.

                      (g)      SEC Reports; Financial Statements. The Company
    has filed all reports required to be filed by it under the Securities Act
    and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
    for the two years preceding the date hereof (or such shorter period as the
    Company was required by law to file such material) (the foregoing materials
    being collectively referred to herein as the "SEC REPORTS" and, together
    with this Agreement and the Schedules to this Agreement, the "DISCLOSURE
    MATERIALS") on a timely basis or has received a valid extension of such time
    of filing and has filed any such SEC Reports prior to the expiration of any
    such extension. The Company has made available to the Purchasers copies of
    all SEC Reports filed within the ten (10) days preceding the date hereof. As
    of their respective dates, the SEC Reports complied in all material respects
    with the requirements of the Securities Act and the Exchange Act and the
    rules and regulations of the Commission promulgated thereunder, and none of
    the SEC Reports, when filed, contained any untrue statement of a material
    fact or omitted to state a material fact required to be stated therein or
    necessary in order to make the statements therein, in the light of the
    circumstances under which they were made, not misleading. The financial
    statements of the Company included in the SEC Reports comply in all material
    respects with applicable accounting requirements and the rules and
    regulations of the Commission with respect thereto as in effect at the time
    of filing. Such financial statements have been prepared in accordance with
    United States generally accepted accounting principles applied on a
    consistent basis during the periods involved ("GAAP"), except as may be
    otherwise specified in such financial statements or the notes thereto or in
    the case of unaudited financial statements, as permitted by Form 10-Q of the
    Commission, and fairly present in all material respects the financial
    position of the Company and its consolidated subsidiaries as of and for the
    dates thereof and the results of operations and cash flows for the periods
    then ended, subject, in the case of unaudited statements, to normal,
    immaterial, year-end audit adjustments. All material agreements, as such
    contracts are defined in Section 601(a)(10) of Regulation S-K under the
    Securities Act, to which the Company or any Subsidiary is a party or to
    which the property or assets of the Company or any Subsidiary are subject
    are included as part of or specifically identified in the SEC Reports.

                      (h)      Material Changes. Since the date of the latest
    audited financial statements included within the SEC Reports, except as
    specifically disclosed in the SEC Reports, (i) there has been no event,
    occurrence or development that, individually or in the aggregate, has had or
    that could result in a Material Adverse Effect, (ii) the Company has not
    incurred any liabilities (contingent or otherwise) other than (A) trade
    payables and accrued expenses incurred in the ordinary course of business
    consistent with past practice and (B) liabilities not required to be
    reflected in the Company's financial statements pursuant to GAAP or required
    to be disclosed in filings made with the Commission, (iii) the Company has
    not altered its method of accounting or the identity of its auditors, (iv)
    the Company has not

                                       8

<PAGE>

    declared or made any dividend or distribution of cash or other property to
    its stockholders or purchased, redeemed or made any agreements to purchase
    or redeem any shares of its capital stock, and (v) the Company has not
    issued any equity securities to any officer, director or Affiliate, except
    pursuant to existing Company stock option and stock purchase plans.

                      (i)      Absence of Litigation. Except as set forth in
    Schedule 3.1(i), there is no action, suit, claim, proceeding, inquiry or
    investigation before or by any court, public board, government agency,
    self-regulatory organization or body pending or, to the knowledge of the
    Company, overtly threatened against or affecting the Company or any of its
    Subsidiaries that could, individually or in the aggregate, have a Material
    Adverse Effect. Schedule 3.1(i) contains a complete list and summary
    description of any pending or, to the knowledge of the Company, threatened
    proceeding against or affecting the Company or any of its Subsidiaries that
    could individually or in the aggregate, have a Material Adverse Effect.

                      (j)      Compliance. Neither the Company nor any
    Subsidiary (i) is in default under or in violation of (and no event has
    occurred that has not been waived that, with notice or lapse of time or
    both, would result in a default by the Company or any Subsidiary under), nor
    has the Company or any Subsidiary received notice of a claim that it is in
    default under or that it is in violation of, any indenture, loan or credit
    agreement or any other agreement or instrument to which it is a party or by
    which it or any of its properties is bound (whether or not such default or
    violation has been waived), (ii) is in violation of any order of any court,
    arbitrator or governmental body, or (iii) is or has been in violation of any
    statute, rule or regulation of any governmental authority, including without
    limitation all foreign, federal, state and local laws relating to taxes,
    environmental protection, occupational health and safety, product quality
    and safety and employment and labor matters, except in each case as could
    not, individually or in the aggregate, have or result in a Material Adverse
    Effect.

                      (k)      Title to Assets. The Company and the Subsidiaries
    have good and marketable title in fee simple to all real property owned by
    them that is material to the business of the Company and the Subsidiaries
    and good and marketable title in all personal property owned by them that is
    material to the business of the Company and the Subsidiaries, in each case
    free and clear of all Liens, except for Liens as do not materially affect
    the value of such property and do not materially interfere with the use made
    and proposed to be made of such property by the Company and the
    Subsidiaries. Any real property and facilities held under lease by the
    Company and the Subsidiaries are held by them under valid, subsisting and
    enforceable leases of which the Company and the Subsidiaries are in
    compliance.

                      (l)      Certain Fees. Except for the fees to Olympus
    Securities, LLC and described in Schedule 3.1(l), all of which are payable
    to registered broker-dealers, no brokerage or finder's fees or commissions
    are or will be payable by the Company to any broker, financial advisor or
    consultant, finder, placement agent, investment banker, bank or other Person
    with respect to the transactions contemplated by this Agreement, and the
    Company has not taken any action that would cause any Purchaser to be liable
    for any such fees or commissions.

                      (m)      Private Placement. Neither the Company nor any
    Person acting on the Company's behalf has sold or offered to sell or
    solicited any offer to buy the Securities by

                                       9

<PAGE>

    means of any form of general solicitation or advertising. Neither the
    Company nor any of its Affiliates nor any Person acting on the Company's
    behalf has, directly or indirectly, at any time within the past six months,
    made any offer or sale of any security or solicitation of any offer to buy
    any security under circumstances that would (i) eliminate the availability
    of the exemption from registration under Regulation D under the Securities
    Act in connection with the offer and sale of the Securities as contemplated
    hereby or (ii) cause the offering of the Securities pursuant to the
    Transaction Documents to be integrated with prior offerings by the Company
    for purposes of any applicable law, regulation or stockholder approval
    provisions, including, without limitation, under the rules and regulations
    of any Trading Market. The Company is not, and is not an Affiliate of, an
    "investment company" within the meaning of the Investment Company Act of
    1940, as amended. The Company is not a United States real property holding
    corporation within the meaning of the Foreign Investment in Real Property
    Tax Act of 1980.

                      (n)      Form S-3 Eligibility. The Company is eligible to
    register its Common Stock for resale by the Purchasers using Form S-3
    promulgated under the Securities Act.

                      (o)      Listing and Maintenance Requirements. Except as
    described in the Company's Annual Report for the year ended December 31,
    2002 filed on Form 10-K with the Commission on March 28, 2003 (the "ANNUAL
    REPORT"), the Company has not, in the two years preceding the date hereof,
    received notice (written or oral) from any Trading Market on which the
    Common Stock is or has been listed or quoted to the effect that the Company
    is not in compliance with the listing or maintenance requirements of such
    Trading Market.

                      (p)      Registration Rights. Except as described in
    Schedule 3.1(p), the Company has not granted or agreed to grant to any
    Person any rights (including "piggy-back" registration rights) to have any
    securities of the Company registered with the Commission or any other
    governmental authority that have not been satisfied.

                      (q)      Application of Takeover Protections. There is no
    control share acquisition, business combination, poison pill (including any
    distribution under a rights agreement) or other similar anti-takeover
    provision under the Company's charter documents or the laws of its state of
    incorporation that is or could become applicable to any of the Purchasers as
    a result of the Purchasers and the Company fulfilling their obligations or
    exercising their rights under the Transaction Documents, including, without
    limitation, as a result of the Company's issuance of the Securities and the
    Purchasers' ownership of the Securities.

                      (r)      Disclosure. The Company confirms that neither it
    nor any other Person acting on its behalf has provided any of the Purchasers
    or their agents or counsel with any information that constitutes or might
    constitute material, nonpublic information. The Company understands and
    confirms that each of the Purchasers will rely on the foregoing
    representations in effecting transactions in securities of the Company. All
    disclosure provided to the Purchasers regarding the Company, its business
    and the transactions contemplated hereby, including the Schedules to this
    Agreement, furnished by or on behalf of the Company are true and correct and
    do not contain any untrue statement of a material fact or omit to state any
    material fact necessary in order to make the statements made therein, in the
    light of the

                                       10

<PAGE>

    circumstances under which they were made, not misleading. No event or
    circumstance has occurred or information exists with respect to the Company
    or any of its Subsidiaries or its or their business, properties, prospects,
    operations or financial conditions, which, under applicable law, rule or
    regulation, requires public disclosure or announcement by the Company but
    which has not been so publicly announced or disclosed, except, until such
    time as the press release is issued as contemplated by Section 4.6, the
    execution of this Agreement. The Company acknowledges and agrees that no
    Purchaser makes or has made any representations or warranties with respect
    to the transactions contemplated hereby other than those specifically set
    forth in Section 3.2.

                      (s)      Acknowledgment Regarding Purchasers' Purchase of
    Securities. The Company acknowledges and agrees that each of the Purchasers
    is acting solely in the capacity of an arm's length purchaser with respect
    to this Agreement and the transactions contemplated hereby. The Company
    further acknowledges that no Purchaser is acting as a financial advisor or
    fiduciary of the Company or any other Purchaser (or in any similar capacity)
    with respect to this Agreement and the transactions contemplated hereby and
    any advice given by any Purchaser or any of their respective representatives
    or agents in connection with this Agreement and the transactions
    contemplated hereby is merely incidental to such Purchaser's purchase of the
    Securities. The Company further represents to each Purchaser that the
    Company's decision to enter into this Agreement has been based solely on the
    independent evaluation of the transactions contemplated hereby by the
    Company and its representatives.

                      (t)      Patents and Trademarks. The Company and the
    Subsidiaries have, or have rights to use, all patents, patent applications,
    trademarks, trademark applications, service marks, trade names, copyrights,
    licenses and other similar rights that are necessary or material for use in
    connection with their respective businesses as described in the SEC Reports
    and which the failure to so have could have a Material Adverse Effect
    (collectively, the "INTELLECTUAL PROPERTY RIGHTS"). Neither the Company nor
    any Subsidiary has received a written notice that the Intellectual Property
    Rights used by the Company or any Subsidiary violates or infringes upon the
    rights of any Person. To the knowledge of the Company, all such Intellectual
    Property Rights are enforceable and there is no existing infringement by
    another Person of any of the Intellectual Property Rights.

                      (u)      Insurance. The Company and the Subsidiaries are
    insured by insurers of recognized financial responsibility against such
    losses and risks and in such amounts as are prudent and customary in the
    businesses in which the Company and the Subsidiaries are engaged. Neither
    the Company nor any Subsidiary has any reason to believe that it will not be
    able to renew its existing insurance coverage as and when such coverage
    expires or to obtain similar coverage from similar insurers as may be
    necessary to continue its business.

                      (v)      Regulatory Permits. The Company and the
    Subsidiaries possess all certificates, authorizations and permits issued by
    the appropriate federal, state, local or foreign regulatory authorities
    necessary to conduct their respective businesses as described in the SEC
    Reports, except where the failure to possess such permits could not,
    individually or in the aggregate, have or result in a Material Adverse
    Effect ("MATERIAL PERMITS"), and neither the Company nor any Subsidiary has
    received any notice of proceedings relating to the revocation or
    modification of any Material Permit.

                                       11

<PAGE>

                      (w)      Transactions With Affiliates and Employees.
    Except as set forth in the Annual Report, none of the officers or directors
    of the Company and, to the knowledge of the Company, none of the employees
    of the Company is presently a party to any transaction with the Company or
    any Subsidiary (other than for services as employees, officers and
    directors), including any contract, agreement or other arrangement providing
    for the furnishing of services to or by, providing for rental of real or
    personal property to or from, or otherwise requiring payments to or from any
    officer, director or such employee or, to the knowledge of the Company, any
    entity in which any officer, director, or any such employee has a
    substantial interest or is an officer, director, trustee or partner.

                      (x)      Solvency. Based on the financial condition of the
    Company as of the Closing Date, (i) the Company's fair saleable value of its
    assets exceeds the amount that will be required to be paid on or in respect
    of the Company's existing debts and other liabilities (including known
    contingent liabilities) as they mature; (ii) the Company's assets do not
    constitute unreasonably small capital to carry on its business for the
    current fiscal year as now conducted and as proposed to be conducted
    including its capital needs taking into account the particular capital
    requirements of the business conducted by the Company, and projected capital
    requirements and capital availability thereof; and (iii) the current cash
    flow of the Company, together with the proceeds the Company would receive,
    were it to liquidate all of its assets, after taking into account all
    anticipated uses of the cash, would be sufficient to pay all amounts on or
    in respect of its debt when such amounts are required to be paid. The
    Company does not intend to incur debts beyond its ability to pay such debts
    as they mature (taking into account the timing and amounts of cash to be
    payable on or in respect of its debt).

                      (y)      Internal Accounting Controls. The Company and the
    Subsidiaries maintain a system of internal accounting controls sufficient to
    provide reasonable assurance that (i) transactions are executed in
    accordance with management's general or specific authorizations, (ii)
    transactions are recorded as necessary to permit preparation of financial
    statements in conformity with generally accepted accounting principles and
    to maintain asset accountability, (iii) access to assets is permitted only
    in accordance with management's general or specific authorization, and (iv)
    the recorded accountability for assets is compared with the existing assets
    at reasonable intervals and appropriate action is taken with respect to any
    differences.

         3.2      Representations and Warranties of the Purchasers. Each
Purchaser hereby, as to itself only and for no other Purchaser, represents and
warrants to the Company as follows:

                      (a)      Organization; Authority. Such Purchaser is an
    entity duly organized, validly existing and in good standing under the laws
    of the jurisdiction of its organization with the requisite corporate or
    partnership power and authority to enter into and to consummate the
    transactions contemplated by the Transaction Documents and otherwise to
    carry out its obligations hereunder and thereunder. The purchase by such
    Purchaser of the Shares and the Warrants hereunder has been duly authorized
    by all necessary action on the part of such Purchaser. This Agreement has
    been duly executed and delivered by such Purchaser and constitutes the valid
    and binding obligation of such Purchaser, enforceable against it in
    accordance with its terms.

                                       12

<PAGE>

                      (b)      Investment Intent. Such Purchaser is acquiring
    the Securities as principal for its own account for investment purposes only
    and not with a view to or for distributing or reselling such Securities or
    any part thereof, without prejudice, however, to such Purchaser's right,
    subject to the provisions of this Agreement, at all times to sell or
    otherwise dispose of all or any part of such Securities pursuant to an
    effective registration statement under the Securities Act or under an
    exemption from such registration and in compliance with applicable federal
    and state securities laws. Nothing contained herein shall be deemed a
    representation or warranty by such Purchaser to hold Securities for any
    period of time. Such Purchaser does not have any agreement or understanding,
    directly or indirectly, with any Person to distribute any of the Securities.

                      (c)      Purchaser Status. At the time such Purchaser was
    offered the Shares and the Warrants, it was, and at the date hereof it is,
    an "accredited investor" as defined in Rule 501(a) under the Securities Act.

                      (d)      Experience of such Purchaser. Such Purchaser,
    either alone or together with its representatives, has such knowledge,
    sophistication and experience in business and financial matters so as to be
    capable of evaluating the merits and risks of the prospective investment in
    the Securities, and has so evaluated the merits and risks of such
    investment. Such Purchaser is able to bear the economic risk of an
    investment in the Securities and, at the present time, is able to afford a
    complete loss of such investment.

                      (e)      Access to Information. Such Purchaser
    acknowledges that it has reviewed the Disclosure Materials and has been
    afforded (i) the opportunity to ask such questions as it has deemed
    necessary of, and to receive answers from, representatives of the Company
    concerning the terms and conditions of the offering of the Securities and
    the merits and risks of investing in the Securities; (ii) access to
    information about the Company and the Subsidiaries and their respective
    financial condition, results of operations, business, properties, management
    and prospects sufficient to enable it to evaluate its investment; and (iii)
    the opportunity to obtain such additional information that the Company
    possesses or can acquire without unreasonable effort or expense that is
    necessary to make an informed investment decision with respect to the
    investment. Neither such inquiries nor any other investigation conducted by
    or on behalf of such Purchaser or its representatives or counsel shall
    modify, amend or affect such Purchaser's right to rely on the truth,
    accuracy and completeness of the Disclosure Materials and the Company's
    representations and warranties contained in the Transaction Documents.

                      (f)      No Short Positions or Stock Ownership. Each
    Purchaser has not, as of the Closing Date, entered into any Short Sales. For
    purposes of this Section 3.2(f), a "SHORT SALE" by a Purchaser means a sale
    of Common Stock that is marked as a short sale and that is executed at a
    time when such Purchaser has no equivalent offsetting long position in the
    Common Stock. For purposes of determining whether a Purchaser has an
    equivalent offsetting long position in the Common Stock, all Common Stock
    and all Common Stock that would be issuable upon conversion or exercise in
    full of all Options then held by such Purchaser (assuming that such Options
    were then fully convertible or exercisable, notwithstanding any provisions
    to the contrary, and giving effect to any conversion or exercise price
    adjustments scheduled to take effect in the future) shall be deemed to be
    held

                                       13

<PAGE>

    long by such Purchaser. The Purchasers are not, immediately prior to the
    Closing Date, the beneficial owners of any of the Company's capital stock.

                                   ARTICLE IV
                         OTHER AGREEMENTS OF THE PARTIES

         4.1      Transfer Restrictions.

                      (a)      Securities may only be disposed of pursuant to an
    effective registration statement under the Securities Act or pursuant to an
    available exemption from the registration requirements of the Securities
    Act, and in compliance with any applicable state securities laws. In
    connection with any transfer of Securities other than pursuant to an
    effective registration statement or to the Company or pursuant to Rule
    144(k), except as otherwise set forth herein, the Company may require the
    transferor to provide to the Company an opinion of counsel selected by the
    transferor, the form and substance of which opinion shall be reasonably
    satisfactory to the Company, to the effect that such transfer does not
    require registration under the Securities Act. Notwithstanding the
    foregoing, the Company hereby consents to and agrees to register on the
    books of the Company and with its Transfer Agent, without any such legal
    opinion, any transfer of Securities by a Purchaser to an Affiliate of such
    Purchaser, provided that the transferee certifies to the Company that it is
    an "accredited investor" as defined in Rule 501(a) under the Securities Act.

                      (b)      The Purchasers agree to the imprinting, so long
    as is required by this Section 4.1(b), of the following legend on any
    certificate evidencing Securities:

         [NEITHER] THESE SECURITIES [NOR THE SECURITIES INTO WHICH THESE
         SECURITIES ARE EXERCISABLE] HAVE [NOT] BEEN REGISTERED WITH THE
         SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
         STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
         SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND,
         ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
         REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
         AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
         REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
         APPLICABLE STATE SECURITIES LAWS. NOTWITHSTANDING THE FOREGOING, THESE
         SECURITIES [AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE
         SECURITIES] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
         ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY SUCH
         SECURITIES.

Certificates evidencing Securities shall not be required to contain such legend
or any other legend (i) following any sale of such Securities while a
Registration Statement covering the resale of such Securities is effective under
the Securities Act, provided that the prospectus delivery requirements of the
Securities Act have been met, or (ii) following any sale of such

                                       14

<PAGE>

Securities pursuant to Rule 144, or (iii) if such Securities are eligible for
sale under Rule 144(k), or (iv) if such legend is not required under applicable
requirements of the Securities Act (including judicial interpretations and
pronouncements issued by the Staff of the Commission). The Company shall cause
its counsel to issue the legal opinion included in the Transfer Agent
Instructions to the Transfer Agent on the Effective Date. Following the
Effective Date or at such earlier time as a legend is no longer required for
certain Securities, the Company will no later than three Trading Days following
the delivery by a Purchaser to the Company or the Transfer Agent of a legended
certificate representing such Securities and following delivery by a Purchaser
to the Company or Company Counsel of a signed and completed notice of sale
representing that the prospectus delivery requirements of the Securities Act
have been met with respect to such sale, deliver or cause to be delivered to
such Purchaser a certificate representing such Securities that is free from all
restrictive and other legends. The Company may not make any notation on its
records or give instructions to any transfer agent of the Company that enlarge
the restrictions on transfer set forth in this Section.

                      (c)      The Company acknowledges and agrees that a
    Purchaser may from time to time pledge or grant a security interest in some
    or all of the Securities in connection with a bona fide margin agreement or
    other loan or financing arrangement secured by the Securities and, if
    required under the terms of such agreement, loan or arrangement, such
    Purchaser may transfer pledged or secured Securities to the pledgees or
    secured parties. Such a pledge or transfer would not be subject to approval
    of the Company and no legal opinion of the pledgee, secured party or pledgor
    shall be required in connection therewith, but such legal opinion may be
    required in connection with a subsequent transfer following default by the
    Purchaser transferee of the pledge. Further, no notice shall be required of
    such pledge. At the appropriate Purchaser's expense, the Company will
    execute and deliver such reasonable documentation as a pledgee or secured
    party of Securities may reasonably request in connection with a pledge or
    transfer of the Securities, including the preparation and filing of any
    required prospectus supplement under Rule 424(b)(3) of the Securities Act or
    other applicable provision of the Securities Act to appropriately amend the
    list of selling stockholders thereunder.

         4.2      Furnishing of Information. As long as any Purchaser owns
Securities, the Company covenants to timely file (or obtain extensions in
respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the
Exchange Act. Upon the request of any Purchaser, the Company shall deliver to
such Purchaser a written certification of a duly authorized officer as to
whether it has complied with the preceding sentence. During the earlier of (i)
the date two years from the Closing Date or (ii) as long as any Purchaser owns
Securities, if the Company is not required to file reports pursuant to such
laws, it will prepare and furnish to the Purchasers and make publicly available
in accordance with paragraph (c) of Rule 144 such information as is required for
the Purchasers to sell the Securities under Rule 144. The Company further
covenants that it will take such further action as any holder of Securities may
reasonably request to satisfy the provisions of Rule 144 applicable to the
issuer of securities relating to transactions for the sale of securities
pursuant to Rule 144.

         4.3      Integration. The Company shall not, and shall use its best
efforts to ensure that no Affiliate of the Company shall, sell, offer for sale
or solicit offers to buy or otherwise negotiate

                                       15

<PAGE>

in respect of any security (as defined in Section 2 of the Securities Act) that
would be integrated with the offer or sale of the Securities in a manner that
would require the registration under the Securities Act of the sale of the
Securities to the Purchasers, or that would be integrated with the offer or sale
of the Securities for purposes of the rules and regulations of any Trading
Market.

         4.4      Reservation of Securities. The Company shall maintain a
reserve from its duly authorized shares of Common Stock for issuance pursuant to
the Transaction Documents in such amount as may be required to fulfill its
obligations in full under the Transaction Documents. In the event that at any
time the then authorized shares of Common Stock are insufficient for the Company
to satisfy its obligations in full under the Transaction Documents, the Company
shall promptly take such actions as may be required to increase the number of
authorized shares.

         4.5      Subsequent Placements.

                      (a)      From the date hereof until the Effective Date
    (the "BLOCKOUT PERIOD"), the Company will not, directly or indirectly,
    offer, sell, grant any option to purchase, or otherwise dispose of (or
    announce any offer, sale, grant or any option to purchase or other
    disposition of) any of its or the Subsidiaries' equity or equity equivalent
    securities, including without limitation any debt, preferred stock or other
    instrument or security that is, at any time during its life and under any
    circumstances, convertible into or exchangeable or exercisable for Common
    Stock or Common Stock Equivalents (any such offer, sale, grant, disposition
    or announcement being referred to as a "SUBSEQUENT PLACEMENT"). The
    restrictions contained in this Section 4.5 shall not apply to Excluded
    Stock.

                      (b)      From the end of the Blockout Period until the one
    year anniversary thereof, the Company will not, directly or indirectly,
    effect any Subsequent Placement unless the Company shall have first complied
    with this Section 4.5(b).

                           (i)      Each Purchaser shall have a right of first
         refusal to purchase up to its pro rata share in any Subsequent
         Placement. Each Purchaser's pro rata share is equal to the ratio of (x)
         the number of Shares and Warrant Shares (assuming full exercise of the
         Warrants) which such Purchaser purchased on the Closing Date to (y) the
         total number of shares of the Company's Common Stock (assuming full
         exercise of the Warrants) outstanding on the Closing Date.

                           (ii)     If the Company proposes to effect any
         Subsequent Offering, it shall give each Purchaser written notice of its
         intention, describing the securities offered (the "OFFERED
         SECURITIES"), identify the Persons or entities (if known) to which or
         with which the Offered Securities are to be offered, issued, sold or
         exchanged, the price (or the anticipated mechanism for determining the
         price) and the terms and conditions upon which the Company proposes to
         issue the same (the "NOTICE"). Each Purchaser shall have not less than
         seven (7) Trading Days from the giving of such Notice to agree to
         purchase up to its pro rata share of the Offered Securities for the
         price and upon the terms and conditions specified in the Notice by
         providing written notice to the Company and stating therein the
         quantity of Offered Securities to be purchased. Notwithstanding the
         foregoing, the Company shall not be required to offer or sell such
         securities to any

                                       16

<PAGE>

         Purchaser who would cause the Company to be in violation of applicable
         federal securities laws by virtue of such offer or sale.

                           (iii)    If the Purchasers fail to exercise in full
         the rights of first refusal (such securities refused, the "REFUSED
         SECURITIES"), the Company shall have 10 days thereafter to sell the
         Offered Securities in respect of which the Purchasers' rights were not
         exercised, but only to the offerees described in the Notice (if so
         described therein) and only at a price and upon general terms and
         conditions materially no more favorable to the purchasers thereof than
         specified in the Notice to the Purchasers pursuant to Section 4.5(b)
         hereof. If the Company has not sold such Offered Securities within 10
         days of the Notice provided pursuant to Section 4(b)(ii), the Company
         shall not thereafter issue or sell any securities, without first
         offering such Offered Securities to the Purchasers in the manner
         provided above.

                           (iv)     Upon the closing of the issuance, sale or
         exchange of all or less than all of the Refused Securities, the
         Purchasers shall acquire from the Company, and the Company shall issue
         to the Purchasers, the number or amount of Offered Securities specified
         in the notices of acceptance, upon the terms and conditions specified
         in the Notice. The purchase by the Purchasers, of any Offered
         Securities is subject in all cases to the preparation, execution and
         delivery by the Company and the Purchasers of a purchase agreement
         relating to such Offered Securities reasonably satisfactory in form and
         substance to the Purchasers and their respective counsel.

         4.6      Securities Laws Disclosure; Publicity. The Company shall, on
or before 9:30a.m., Eastern Standard Time, on September 25, 2003, issue a press
release acceptable to the Purchasers disclosing the transactions contemplated
hereby. Within one Trading Day following the Closing Date, the Company shall
file a Current Report on Form 8-K with the Commission (the "8-K FILING")
describing the transactions contemplated by the Transaction Documents and
including as exhibits to such Current Report on Form 8-K this Agreement and the
form of Warrants, in the form required by the Exchange Act. Thereafter, the
Company shall timely file any filings and notices required by the Commission or
applicable law with respect to the transactions contemplated hereby and provide
copies thereof to the Purchasers promptly after filing. Except with respect to
the 8-K Filing and the press release referenced above (a copy of which will be
provided to the Purchasers for their review as early as practicable prior to its
filing), the Company shall, at least two Trading Days prior to the filing or
dissemination of any disclosure required by this paragraph, provide a copy
thereof to the Purchasers for their review. The Company and the Purchasers shall
consult with each other in issuing any press releases or otherwise making public
statements or filings and other communications with the Commission or any
regulatory agency or Trading Market with respect to the transactions
contemplated hereby, and neither party shall issue any such press release or
otherwise make any such public statement, filing or other communication without
the prior consent of the other, except if such disclosure is required by law, in
which case the disclosing party shall promptly provide the other party with
prior notice of such public statement, filing or other communication.
Notwithstanding the foregoing, the Company shall not publicly disclose the name
of any Purchaser, or include the name of any Purchaser in any filing with the
Commission or any regulatory agency or Trading Market, without the prior written
consent of such Purchaser, except to the extent such disclosure (but not any
disclosure as to the controlling Persons thereof) is required by law or Trading

                                       17

<PAGE>

Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure. The Company shall not, and shall cause each of
its Subsidiaries and its and each of their respective officers, directors,
employees and agents not to, provide any Purchaser with any material nonpublic
information regarding the Company or any of its Subsidiaries from and after the
filing of the 8-K Filing without the express written consent of such Purchaser.
No Purchaser shall have any liability to the Company, its Subsidiaries, or any
of its or their respective officers, directors, employees, stockholders or
agents for any such disclosure. Subject to the foregoing, neither the Company
nor any Purchaser shall issue any press releases or any other public statements
with respect to the transactions contemplated hereby; provided, however, that
the Company shall be entitled, without the prior approval of any Purchaser, to
make any press release or other public disclosure with respect to such
transactions (i) in substantial conformity with the 8-K Filing and
contemporaneously therewith and (ii) as is required by applicable law and
regulations (provided that in the case of clause (i) each Purchaser shall be
consulted by the Company in connection with any such press release or other
public disclosure prior to its release). Each press release disseminated during
the 12 months preceding the date of this Agreement did not at the time of
release contain any untrue statement of a material fact.

         4.7      Use of Proceeds. The Company shall use the net proceeds from
the sale of the Securities hereunder for working capital purposes and not for
the satisfaction of any portion of the Company's debt (other than payment of
trade payables and accrued expenses in the ordinary course of the Company's
business and consistent with prior practices), to redeem any Company equity or
equity-equivalent securities or to settle any outstanding litigation.

         4.8      Reimbursement. If any Purchaser or any of its Affiliates or
any officer, director, partner, controlling Person, employee or agent of a
Purchaser or any of its Affiliates (a "RELATED PERSON") becomes involved in any
capacity in any Proceeding brought by or against any Person in connection with
or as a result of any misrepresentation, breach or inaccuracy of any
representation, warranty, covenant or agreement made by the Company in any
Transaction Documents, the Company will indemnify and hold harmless such
Purchaser or Related Person for its reasonable legal and other expenses
(including the costs of any investigation, preparation and travel) and for any
Losses incurred in connection therewith, as such expenses or Losses are
incurred, excluding only Losses that result directly from such Purchaser's or
Related Person's gross negligence or willful misconduct. The conduct of any
Proceedings for which indemnification is available under this paragraph shall be
governed by Section 6.4(c) below. The indemnification obligations of the Company
under this paragraph shall be in addition to any liability that the Company may
otherwise have and shall be binding upon and inure to the benefit of any
successors, assigns, heirs and personal representatives of the Purchasers and
any such Related Persons. The Company also agrees that neither the Purchasers
nor any Related Persons shall have any liability to the Company or any Person
asserting claims on behalf of or in right of the Company in connection with or
as a result of the transactions contemplated by the Transaction Documents,
except to the extent that any Losses incurred by the Company result from the
gross negligence or willful misconduct of the applicable Purchaser or Related
Person in connection with such transactions. If the Company breaches its
obligations under any Transaction Document, then, in addition to any other
liabilities the Company may have under any Transaction Document or applicable
law, the Company shall pay or reimburse the Purchasers on demand for all costs
of collection and enforcement (including reasonable attorneys fees and
expenses). Without limiting the generality of the foregoing, the Company
specifically

                                       18

<PAGE>

agrees to reimburse the Purchasers on demand for all costs of enforcing the
indemnification obligations in this paragraph.

                                   ARTICLE V
                                   CONDITIONS

         5.1      Conditions Precedent to the Obligations of the Purchasers. The
obligation of each Purchaser to acquire Securities at the Closing is subject to
the satisfaction or waiver by such Purchaser, at or before the Closing, of each
of the following conditions:

                      (a)      Representations and Warranties. The
    representations and warranties of the Company contained herein shall be true
    and correct in all material respects as of the date when made and as of the
    Closing as though made on and as of such date; and

                      (b)      Performance. The Company and each other Purchaser
    shall have performed, satisfied and complied in all material respects with
    all covenants, agreements and conditions required by the Transaction
    Documents to be performed, satisfied or complied with by it at or prior to
    the Closing.

         5.2      Conditions Precedent to the Obligations of the Company. The
obligation of the Company to sell Securities at the Closing is subject to the
satisfaction or waiver by the Company, at or before the Closing, of each of the
following conditions:

                      (a)      Representations and Warranties. The
    representations and warranties of the Purchasers contained herein shall be
    true and correct in all material respects as of the date when made and as of
    the Closing Date as though made on and as of such date; and

                      (b)      Performance. The Purchasers shall have performed,
    satisfied and complied in all material respects with all covenants,
    agreements and conditions required by the Transaction Documents to be
    performed, satisfied or complied with by the Purchasers at or prior to the
    Closing.

                                   ARTICLE VI
                               REGISTRATION RIGHTS

         6.1      Shelf Registration

                      (a)      As promptly as possible, and in any event on or
    prior to the Filing Date, the Company shall prepare and file with the
    Commission a "Shelf" Registration Statement covering the resale of all
    Registrable Securities for an offering to be made on a continuous basis
    pursuant to Rule 415. The Registration Statement shall be on Form S-3
    (except if the Company is not then eligible to register for resale the
    Registrable Securities on Form S-3, in which case such registration shall be
    on another appropriate form in accordance herewith as the Purchasers may
    consent) and shall contain (except if otherwise directed by the Purchasers)
    the "Plan of Distribution" attached hereto as Exhibit C.

                      (b)      The Company shall use its commercially reasonably
    efforts to cause the Registration Statement to be declared effective by the
    Commission as promptly as possible

                                       19

<PAGE>

    after the filing thereof, but in any event prior to the Required
    Effectiveness Date, and shall use its best efforts to keep the Registration
    Statement continuously effective under the Securities Act until the fifth
    anniversary of the Effective Date or such earlier date when all Registrable
    Securities covered by such Registration Statement have been sold or may be
    sold without volume restrictions pursuant to Rule 144(k) (the "EFFECTIVENESS
    PERIOD").

                      (c)      The Company shall notify each Purchaser in
    writing promptly (and in any event within one Trading Day) after receiving
    notification from the Commission that the Registration Statement has been
    declared effective.

                      (d)      Upon the occurrence of any Event (as defined
    below) and on every monthly anniversary thereof until the applicable Event
    is cured, as partial relief for the damages suffered therefrom by the
    Purchasers (which remedy shall not be exclusive of any other remedies
    available under this Agreement, at law or in equity), the Company shall pay
    to each Purchaser an amount in cash, as liquidated damages and not as a
    penalty, equal to 1% of the aggregate purchase price paid by such Purchaser
    hereunder. The payments to which a Purchaser shall be entitled pursuant to
    this Section 6.1(d) are referred to herein as "EVENT PAYMENTS". Any Event
    Payments payable pursuant to the terms hereof shall apply on a pro-rata
    basis for any portion of a month prior to the cure of an Event. In the event
    the Company fails to make Event Payments in a timely manner, such Event
    Payments shall bear interest at the rate of 1.5% per month (prorated for
    partial months) until paid in full.

For such purposes, the occurrence of the Registration Statement not being filed
on or prior to the Filing Date or not being declared effective on or prior to
the Required Effectiveness Date shall constitute an "EVENT".

                      (e)      Notwithstanding anything in this Agreement to the
    contrary, the Company may, by written notice to the Purchasers, suspend
    sales under a Registration Statement after the Effective Date thereof and/or
    require that the Purchasers immediately cease the sale of shares of Common
    Stock pursuant thereto and/or defer the filing of any subsequent
    Registration Statement if at any time the Company determines in good faith
    that such Registration Statement contains an untrue statement of a material
    fact or omits to state a material fact required to be stated therein or
    necessary to make the statements therein, in the light of the circumstances
    under which they were made, not misleading and cannot be utilized in
    connection with the sale of shares of Common Stock until it has been
    appropriately amended. Upon receipt of such notice, each Purchaser shall
    immediately discontinue any sales of Registrable Securities pursuant to such
    registration until such Purchaser has received copies of a supplemented or
    amended Prospectus or until such Purchaser is advised in writing by the
    Company that the then-current Prospectus may be used and has received copies
    of any additional or supplemental filings that are incorporated or deemed
    incorporated by reference in such Prospectus. In no event, however, shall
    this right be exercised to suspend sales beyond the period during which (in
    the good faith determination of the Company's Board of Directors) the
    failure to require such suspension would be materially detrimental to the
    Company. Furthermore, in no event may the Company exercise its rights
    hereunder for a period of more than 7 consecutive Trading Days or more than
    20 Trading Days in any twelve month period. Immediately after the end of any
    suspension period under this Section 6.1(e), the Company shall take all
    necessary actions (including filing any required supplemental

                                       20

<PAGE>

    prospectus) to restore the effectiveness of the applicable Registration
    Statement and the ability of the Purchasers to publicly resell their
    Registrable Securities pursuant to such effective Registration Statement.

                      (f)      Except with respect to the 628,877 shares of
    Common Stock held by Takara Bio Inc. and any registration statements filed
    with the Commission prior to the date hereof, the Company shall not, prior
    to the Effective Date of the Registration Statement, prepare and file with
    the Commission a registration statement relating to an offering for its own
    account or the account of others under the Securities Act of any of its
    equity securities.

         6.2      Registration Procedures. In connection with the Company's
registration obligations hereunder, the Company shall:

                      (a)      Not less than three Trading Days prior to the
    filing of a Registration Statement or any related Prospectus or any
    amendment or supplement thereto (specifically excluding any document that
    would be incorporated or deemed to be incorporated therein by reference),
    the Company shall furnish to each Purchaser and any counsel designated by
    any Purchaser (each, a "PURCHASER COUNSEL", and Vertical Ventures, LLC has
    initially designated Proskauer Rose LLP) copies of all such documents
    proposed to be filed, which documents (other than those incorporated or
    deemed to be incorporated by reference) will be subject to the review of
    such Purchasers and each Purchaser Counsel. The Company shall not file a
    Registration Statement or any such Prospectus or any amendments or
    supplements thereto to which Purchasers holding a majority of the
    Registrable Securities shall reasonably object in good faith.

                      (b)      (i) Prepare and file with the Commission such
    amendments, including post-effective amendments, to each Registration
    Statement and the Prospectus used in connection therewith as may be
    necessary to keep the Registration Statement continuously effective as to
    the applicable Registrable Securities for the Effectiveness Period and
    prepare and file with the Commission such additional Registration Statements
    in order to register for resale under the Securities Act all of the
    Registrable Securities; (ii) cause the related Prospectus to be amended or
    supplemented by any required Prospectus supplement, and as so supplemented
    or amended to be filed pursuant to Rule 424; (iii) respond as promptly as
    reasonably possible, and in any event within 15 days, to any comments
    received from the Commission with respect to the Registration Statement or
    any amendment thereto and as promptly as reasonably possible provide the
    Purchasers true and complete copies of all correspondence from and to the
    Commission relating to the Registration Statement; and (iv) comply in all
    material respects with the provisions of the Securities Act and the Exchange
    Act with respect to the disposition of all Registrable Securities covered by
    the Registration Statement during the applicable period in accordance with
    the intended methods of disposition by the Purchasers thereof set forth in
    the Registration Statement as so amended or in such Prospectus as so
    supplemented

                      (c)      Notify the Purchasers of Registrable Securities
    to be sold and each Purchaser Counsel as promptly as reasonably possible,
    and (if requested by any such Person) confirm such notice in writing no
    later than one Trading Day thereafter, of any of the following events: (i)
    the Commission notifies the Company whether there will be a "review"

                                       21

<PAGE>

    of any Registration Statement; (ii) the Commission comments in writing on
    any Registration Statement (in which case the Company shall deliver to each
    Purchaser a copy of such comments and of all written responses thereto);
    (iii) any Registration Statement or any post-effective amendment is declared
    effective; (iv) the Commission or any other Federal or state governmental
    authority requests any amendment or supplement to any Registration Statement
    or Prospectus or requests additional information related thereto; (v) the
    Commission issues any stop order suspending the effectiveness of any
    Registration Statement or initiates any Proceedings for that purpose; (vi)
    the Company receives notice of any suspension of the qualification or
    exemption from qualification of any Registrable Securities for sale in any
    jurisdiction, or the initiation or threat of any Proceeding for such
    purpose; or (vii) the financial statements included in any Registration
    Statement become ineligible for inclusion therein or any statement made in
    any Registration Statement or Prospectus or any document incorporated or
    deemed to be incorporated therein by reference is untrue in any material
    respect or any revision to a Registration Statement, Prospectus or other
    document is required so that it will not contain any untrue statement of a
    material fact or omit to state any material fact required to be stated
    therein or necessary to make the statements therein, in the light of the
    circumstances under which they were made, not misleading.

                      (d)      Use its best efforts to avoid the issuance of or,
    if issued, obtain the withdrawal of (i) any order suspending the
    effectiveness of any Registration Statement, or (ii) any suspension of the
    qualification (or exemption from qualification) of any of the Registrable
    Securities for sale in any jurisdiction, at the earliest practicable moment.

                      (e)      Furnish to each Purchaser and each Purchaser
    Counsel, without charge, at least one conformed copy of each Registration
    Statement and each amendment thereto, including financial statements and
    schedules, all documents incorporated or deemed to be incorporated therein
    by reference, and all exhibits to the extent requested by such Person
    (including those previously furnished or incorporated by reference) promptly
    after the filing of such documents with the Commission.

                      (f)      Promptly deliver to each Purchaser and each
    Purchaser Counsel, without charge, as many copies of the Prospectus or
    Prospectuses (including each form of prospectus) and each amendment or
    supplement thereto as such Persons may reasonably request. The Company
    hereby consents to the use of such Prospectus and each amendment or
    supplement thereto by each of the selling Purchasers in connection with the
    offering and sale of the Registrable Securities covered by such Prospectus
    and any amendment or supplement thereto.

                      (g)      (i) In the time and manner required by each
    Trading Market, prepare and file with such Trading Market an additional
    shares listing application covering all of the Registrable Securities; (ii)
    take all steps necessary to cause such Registrable Securities to be approved
    for listing on each Trading Market as soon as possible thereafter; (iii)
    provide to the Purchasers evidence of such listing; and (iv) maintain the
    listing of such Registrable Securities on each such Trading Market or
    another Eligible Market.

                      (h)      Prior to any public offering of Registrable
    Securities, use its best efforts to register or qualify or cooperate with
    the selling Purchasers and each applicable Purchaser

                                       22

<PAGE>

    Counsel in connection with the registration or qualification (or exemption
    from such registration or qualification) of such Registrable Securities for
    offer and sale under the securities or blue sky laws of such jurisdictions
    within the United States as any Purchaser requests in writing, to keep each
    such registration or qualification (or exemption therefrom) effective during
    the Effectiveness Period and to do any and all other acts or things
    necessary or advisable to enable the disposition in such jurisdictions of
    the Registrable Securities covered by a Registration Statement; provided,
    however, that the Company shall not be obligated to file any general consent
    to service of process or to qualify as a foreign corporation or as a dealer
    in securities in any jurisdiction in which it is not so qualified or to
    subject itself to taxation in respect of doing business in any jurisdiction
    in which it is not otherwise subject.

                      (i)      Cooperate with the Purchasers to facilitate the
    timely preparation and delivery of certificates representing Registrable
    Securities to be delivered to a transferee pursuant to a Registration
    Statement, which certificates shall be free, to the extent permitted by this
    Agreement, of all restrictive legends, and to enable such Registrable
    Securities to be in such denominations and registered in such names as any
    such Purchasers may request.

                      (j)      Upon the occurrence of any event described in
    Section 6.2(c)(vii), as promptly as reasonably possible, prepare a
    supplement or amendment, including a post-effective amendment, to the
    Registration Statement or a supplement to the related Prospectus or any
    document incorporated or deemed to be incorporated therein by reference, and
    file any other required document so that, as thereafter delivered, neither
    the Registration Statement nor such Prospectus will contain an untrue
    statement of a material fact or omit to state a material fact required to be
    stated therein or necessary to make the statements therein, in the light of
    the circumstances under which they were made, not misleading.

                      (k)      Comply with all applicable rules and regulations
    of the Commission.

         6.3      Registration Expenses. The Company shall pay (or reimburse the
Purchasers for) all fees and expenses incident to the performance of or
compliance with this Agreement by the Company, including without limitation (a)
all registration and filing fees and expenses, including without limitation
those related to filings with the Commission, any Trading Market and in
connection with applicable state securities or Blue Sky laws, (b) printing
expenses (including without limitation expenses of printing certificates for
Registrable Securities and of printing prospectuses requested by the
Purchasers), (c) messenger, telephone and delivery expenses, (d) fees and
disbursements of counsel for the Company, (e) fees and expenses of all other
Persons retained by the Company in connection with the consummation of the
transactions contemplated by this Agreement, and (f) all listing fees to be paid
by the Company to the Trading Market.

         6.4      Indemnification

                      (a)      Indemnification by the Company. The Company
    shall, notwithstanding any termination of this Agreement, indemnify and hold
    harmless each Purchaser, the officers, directors, partners, members, agents,
    brokers (including brokers who offer and sell Registrable Securities as
    principal as a result of a pledge or any failure to perform under a margin
    call of

                                       23

<PAGE>

    Common Stock), investment advisors and employees of each of them, each
    Person who controls any such Purchaser (within the meaning of Section 15 of
    the Securities Act or Section 20 of the Exchange Act) and the officers,
    directors, partners, members, agents and employees of each such controlling
    Person, to the fullest extent permitted by applicable law, from and against
    any and all Losses, as incurred, arising out of or relating to any untrue or
    alleged untrue statement of a material fact contained in the Registration
    Statement, any Prospectus or any form of prospectus or in any amendment or
    supplement thereto or in any preliminary prospectus, or arising out of or
    relating to any omission or alleged omission of a material fact required to
    be stated therein or necessary to make the statements therein (in the case
    of any Prospectus or form of prospectus or supplement thereto, in the light
    of the circumstances under which they were made) not misleading, except to
    the extent, but only to the extent, that (i) such untrue statements, alleged
    untrue statements, omissions or alleged omissions are based solely upon
    information regarding such Purchaser furnished in writing to the Company by
    such Purchaser expressly for use therein, or to the extent that such
    information relates to such Purchaser or such Purchaser's proposed method of
    distribution of Registrable Securities and was reviewed and expressly
    approved in writing by such Purchaser expressly for use in the Registration
    Statement, such Prospectus or such form of Prospectus or in any amendment or
    supplement thereto or (ii) in the case of an occurrence of an event of the
    type specified in Section 6.2(c)(v)-(vii), the use by such Purchaser of an
    outdated or defective Prospectus after the Company has notified such
    Purchaser in writing that the Prospectus is outdated or defective and prior
    to the receipt by such Purchaser of the Advice contemplated in Section 6.5.
    The Company shall notify the Purchasers promptly of the institution, threat
    or assertion of any Proceeding of which the Company is aware in connection
    with the transactions contemplated by this Agreement.

                      (b)      Indemnification by Purchasers. Each Purchaser
    shall, severally and not jointly, indemnify and hold harmless the Company,
    its directors, officers, agents and employees, each Person who controls the
    Company (within the meaning of Section 15 of the Securities Act and Section
    20 of the Exchange Act), and the directors, officers, agents or employees of
    such controlling Persons, to the fullest extent permitted by applicable law,
    from and against all Losses (as determined by a court of competent
    jurisdiction in a final judgment not subject to appeal or review) arising
    solely out of any untrue statement of a material fact contained in the
    Registration Statement, any Prospectus, or any form of prospectus, or in any
    amendment or supplement thereto, or arising solely out of any omission of a
    material fact required to be stated therein or necessary to make the
    statements therein (in the case of any Prospectus or form of prospectus or
    supplement thereto, in the light of the circumstances under which they were
    made) not misleading to the extent, but only to the extent, that such untrue
    statement or omission is contained in any information so furnished in
    writing by such Purchaser to the Company specifically for inclusion in such
    Registration Statement or such Prospectus or to the extent that (i) such
    untrue statements or omissions are based solely upon information regarding
    such Purchaser furnished in writing to the Company by such Purchaser
    expressly for use therein, or to the extent that such information relates to
    such Purchaser or such Purchaser's proposed method of distribution of
    Registrable Securities and was reviewed and expressly approved in writing by
    such Purchaser expressly for use in the Registration Statement, such
    Prospectus or such form of Prospectus or in any amendment or supplement
    thereto or (ii) in the case of an occurrence of an event of the type
    specified in Section 6.2(c)(v)-(vii), the use by such Purchaser of an
    outdated or defective Prospectus after the

                                       24

<PAGE>

    Company has notified such Purchaser in writing that the Prospectus is
    outdated or defective and prior to the receipt by such Purchaser of the
    Advice contemplated in Section 6.5. In no event shall the liability of any
    selling Purchaser hereunder be greater in amount than the dollar amount of
    the net proceeds received by such Purchaser upon the sale of the Registrable
    Securities giving rise to such indemnification obligation.

                      (c)      Conduct of Indemnification Proceedings. If any
    Proceeding shall be brought or asserted against any Person entitled to
    indemnity hereunder (an "INDEMNIFIED PARTY"), such Indemnified Party shall
    promptly notify the Person from whom indemnity is sought (the "INDEMNIFYING
    PARTY") in writing, and the Indemnifying Party shall assume the defense
    thereof, including the employment of counsel reasonably satisfactory to the
    Indemnified Party and the payment of all fees and expenses incurred in
    connection with defense thereof; provided, that the failure of any
    Indemnified Party to give such notice shall not relieve the Indemnifying
    Party of its obligations or liabilities pursuant to this Agreement, except
    (and only) to the extent that it shall be finally determined by a court of
    competent jurisdiction (which determination is not subject to appeal or
    further review) that such failure shall have proximately and materially
    adversely prejudiced the Indemnifying Party.

                  An Indemnified Party shall have the right to employ separate
counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such
Indemnified Party or Parties unless: (i) the Indemnifying Party has agreed in
writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have
failed promptly to assume the defense of such Proceeding and to employ counsel
reasonably satisfactory to such Indemnified Party in any such Proceeding; or
(iii) the named parties to any such Proceeding (including any impleaded parties)
include both such Indemnified Party and the Indemnifying Party, and such
Indemnified Party shall have been advised by counsel that a conflict of interest
is likely to exist if the same counsel were to represent such Indemnified Party
and the Indemnifying Party (in which case, if such Indemnified Party notifies
the Indemnifying Party in writing that it elects to employ separate counsel at
the expense of the Indemnifying Party, the Indemnifying Party shall not have the
right to assume the defense thereof and such counsel shall be at the expense of
the Indemnifying Party). The Indemnifying Party shall not be liable for any
settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld. No Indemnifying Party shall, without
the prior written consent of the Indemnified Party, effect any settlement of any
pending Proceeding in respect of which any Indemnified Party is a party, unless
such settlement includes an unconditional release of such Indemnified Party from
all liability on claims that are the subject matter of such Proceeding.

                  All fees and expenses of the Indemnified Party (including
reasonable fees and expenses to the extent incurred in connection with
investigating or preparing to defend such Proceeding in a manner not
inconsistent with this Section) shall be paid to the Indemnified Party, as
incurred, within ten Trading Days of written notice thereof to the Indemnifying
Party (regardless of whether it is ultimately determined that an Indemnified
Party is not entitled to indemnification hereunder; provided, that the
Indemnifying Party may require such Indemnified Party to undertake to reimburse
all such fees and expenses to the extent it is finally judicially determined
that such Indemnified Party is not entitled to indemnification hereunder).

                                       25

<PAGE>

                      (d)      Contribution. If a claim for indemnification
    under Section 6.4(a) or (b) is unavailable to an Indemnified Party (by
    reasons other than the specified exclusions to indemnification), then each
    Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall
    contribute to the amount paid or payable by such Indemnified Party as a
    result of such Losses, in such proportion as is appropriate to reflect the
    relative fault of the Indemnifying Party and Indemnified Party in connection
    with the actions, statements or omissions that resulted in such Losses as
    well as any other relevant equitable considerations. The relative fault of
    such Indemnifying Party and Indemnified Party shall be determined by
    reference to, among other things, whether any action in question, including
    any untrue or alleged untrue statement of a material fact or omission or
    alleged omission of a material fact, has been taken or made by, or relates
    to information supplied by, such Indemnifying Party or Indemnified Party,
    and the parties' relative intent, knowledge, access to information and
    opportunity to correct or prevent such action, statement or omission. The
    amount paid or payable by a party as a result of any Losses shall be deemed
    to include, subject to the limitations set forth in Section 6.4(c), any
    reasonable attorneys' or other reasonable fees or expenses incurred by such
    party in connection with any Proceeding to the extent such party would have
    been indemnified for such fees or expenses if the indemnification provided
    for in this Section was available to such party in accordance with its
    terms.

                  The parties hereto agree that it would not be just and
equitable if contribution pursuant to this Section 6.4(d) were determined by pro
rata allocation or by any other method of allocation that does not take into
account the equitable considerations referred to in the immediately preceding
paragraph. Notwithstanding the provisions of this Section 6.4(d), no Purchaser
shall be required to contribute, in the aggregate, any amount in excess of the
amount by which the proceeds actually received by such Purchaser from the sale
of the Registrable Securities subject to the Proceeding exceeds the amount of
any damages that such Purchaser has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission. No
Person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any Person
who was not guilty of such fraudulent misrepresentation.

                  The indemnity and contribution agreements contained in this
Section are in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties.

         6.5      Dispositions. Each Purchaser agrees that it will comply with
the prospectus delivery requirements of the Securities Act as applicable to it
in connection with sales of Registrable Securities pursuant to the Registration
Statement. Each Purchaser further agrees that, upon receipt of a notice from the
Company of the occurrence of any event of the kind described in Sections
6.2(c)(v), (vi) or (vii), such Purchaser will discontinue disposition of such
Registrable Securities under the Registration Statement until such Purchaser's
receipt of the copies of the supplemented Prospectus and/or amended Registration
Statement contemplated by Section 6.2(j), or until it is advised in writing (the
"ADVICE") by the Company that the use of the applicable Prospectus may be
resumed, and, in either case, has received copies of any additional or
supplemental filings that are incorporated or deemed to be incorporated by
reference in such Prospectus or Registration Statement. The Company may provide
appropriate stop orders to enforce the provisions of this paragraph.

                                       26

<PAGE>

         6.6      No Piggyback on Registrations. Other than pursuant to the
exercise of existing registration rights by certain stockholders of the Company
as specified in Schedule 6.6 hereto, neither the Company nor any of its security
holders (other than the Purchasers in such capacity pursuant hereto) may include
securities of the Company in the Registration Statement other than the
Registrable Securities, and the Company shall not after the date hereof enter
into any agreement providing any such right to any of its security holders.

         6.7      Piggy-Back Registrations. If at any time during the
Effectiveness Period there is not an effective Registration Statement covering
all of the Registrable Securities and the Company shall determine to prepare and
file with the Commission a registration statement relating to an offering for
its own account or the account of others under the Securities Act of any of its
equity securities, other than on Form S-4 or Form S-8 (each as promulgated under
the Securities Act) or their then equivalents relating to equity securities to
be issued solely in connection with any acquisition of any entity or business or
equity securities issuable in connection with stock option or other employee
benefit plans, then the Company shall send to each Purchaser written notice of
such determination and if, within fifteen days after receipt of such notice, any
such Purchaser shall so request in writing, the Company shall include in such
registration statement all or any part of such Registrable Securities such
Purchaser requests to be registered.

                                   ARTICLE VII
                                  MISCELLANEOUS

         7.1      Termination. This Agreement may be terminated by the Company
or any Purchaser, by written notice to the other parties, if the Closing has not
been consummated by the third Trading Day following the date of this Agreement;
provided that no such termination will affect the right of any party to sue for
any breach by the other party (or parties).

         7.2      Fees and Expenses. At the Closing, the Company shall pay to
Vertical Ventures, LLC an aggregate of $20,000 for their legal fees and expenses
incurred in connection with the preparation and negotiation of the Transaction
Documents and related work in connection with the filing of the Registration
Statement with the Commission, of which amount $10,000 has been previously paid
by the Company to Proskauer Rose LLP. In lieu of the foregoing payment, Vertical
Ventures, LLC may retain such amount at the Closing or require the Company to
pay such amount directly to Proskauer Rose LLP. Except as expressly set forth in
the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and
all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company
shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied
in connection with the issuance of the Securities.

         7.3      Entire Agreement. The Transaction Documents, together with the
Exhibits and Schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules. At or
after the Closing, and without further consideration, the Company will execute
and deliver to the Purchasers such further documents as may be reasonably

                                       27

<PAGE>

requested in order to give practical effect to the intention of the parties
under the Transaction Documents. Notwithstanding anything to the contrary
herein, Securities may be assigned to any Person in connection with a bona fide
margin account or other loan or financing arrangement secured by such Company
Securities.

         7.4      Notices. Any and all notices or other communications or
deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective on the earliest of (a) the date of
transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in this Section prior to 6:30 p.m. (New York City
time) on a Trading Day, (b) the next Trading Day after the date of transmission,
if such notice or communication is delivered via facsimile at the facsimile
number specified in this Section on a day that is not a Trading Day or later
than 6:30 p.m. (New York City time) on any Trading Day, (c) the Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight
courier service, or (d) upon actual receipt by the party to whom such notice is
required to be given. The addresses and facsimile numbers for such notices and
communications are those set forth on the signature pages hereof, or such other
address or facsimile number as may be designated in writing hereafter, in the
same manner, by such Person.

         7.5      Amendments; Waivers. No provision of this Agreement may be
waived or amended except in a written instrument signed, in the case of an
amendment, by the Company and each of the Purchasers or, in the case of a
waiver, by the party against whom enforcement of any such waiver is sought. No
waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a
waiver of any subsequent default or a waiver of any other provision, condition
or requirement hereof, nor shall any delay or omission of either party to
exercise any right hereunder in any manner impair the exercise of any such
right. Notwithstanding the foregoing, a waiver or consent to depart from the
provisions hereof with respect to a matter that relates exclusively to the
rights of Purchasers under Article VI and that does not directly or indirectly
affect the rights of other Purchasers may be given by Purchasers holding at
least a majority of the Registrable Securities to which such waiver or consent
relates.

         7.6      Construction. The headings herein are for convenience only, do
not constitute a part of this Agreement and shall not be deemed to limit or
affect any of the provisions hereof. The language used in this Agreement will be
deemed to be the language chosen by the parties to express their mutual intent,
and no rules of strict construction will be applied against any party.

         7.7      Successors and Assigns. This Agreement shall be binding upon
and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the Purchasers. Any Purchaser may
assign its rights under this Agreement to any Person to whom such Purchaser
assigns or transfers any Securities, provided such transferee agrees in writing
to be bound, with respect to the transferred Securities, by the provisions
hereof that apply to the "Purchasers." Notwithstanding anything to the contrary
herein, Securities may be assigned to any Person in connection with a bona fide
margin account or other loan or financing arrangement secured by such
Securities.

                                       28

<PAGE>

         7.8      No Third-Party Beneficiaries. This Agreement is intended for
the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced
by, any other Person, except that each Related Person is an intended third party
beneficiary of Section 4.8 and each Indemnified Party is an intended third party
beneficiary of Section 6.4 and (in each case) may enforce the provisions of such
Sections directly against the parties with obligations thereunder.

         7.9      Governing Law; Venue; Waiver Of Jury Trail. ALL QUESTIONS
CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK. THE COMPANY AND PURCHASERS HEREBY IRREVOCABLY
SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN
THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE
BROUGHT BY THE COMPANY OR ANY PURCHASER HEREUNDER, IN CONNECTION HEREWITH OR
WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH
RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY
IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING
BROUGHT BY THE COMPANY OR ANY PURCHASER, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR
PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF
PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR
PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR
OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN
EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL
CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING
CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS
IN ANY MANNER PERMITTED BY LAW. THE COMPANY AND PURCHASERS HEREBY WAIVE ALL
RIGHTS TO A TRIAL BY JURY.

         7.10     Survival. The representations, warranties, agreements and
covenants contained herein shall survive the Closing and the delivery and/or
exercise of the Securities, as applicable.

         7.11     Execution. This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the
same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that both
parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile signature page
were an original thereof.

         7.12     Severability. If any provision of this Agreement is held to be
invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be
affected or impaired thereby and the parties

                                       29

<PAGE>

will attempt to agree upon a valid and enforceable provision that is a
reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.

         7.13     Rescission and Withdrawal Right. Notwithstanding anything to
the contrary contained in (and without limiting any similar provisions of) the
Transaction Documents, whenever any Purchaser exercises a right, election,
demand or option under a Transaction Document and the Company does not timely
perform its related obligations within the periods therein provided, then such
Purchaser may rescind or withdraw, in its sole discretion from time to time upon
written notice to the Company, any relevant notice, demand or election in whole
or in part without prejudice to its future actions and rights.

         7.14     Replacement of Securities. If any certificate or instrument
evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon
cancellation thereof, or in lieu of and substitution therefor, a new certificate
or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction and customary and reasonable
indemnity, if requested. The applicants for a new certificate or instrument
under such circumstances shall also pay any reasonable third-party costs
associated with the issuance of such replacement Securities.

         7.15     Remedies. In addition to being entitled to exercise all rights
provided herein or granted by law, including recovery of damages, each of the
Purchasers and the Company will be entitled to specific performance under the
Transaction Documents. The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of
obligations described in the foregoing sentence and hereby agrees to waive in
any action for specific performance of any such obligation the defense that a
remedy at law would be adequate.

         7.16     Payment Set Aside. To the extent that the Company makes a
payment or payments to any Purchaser hereunder or pursuant to the Warrants or
any Purchaser enforces or exercises its rights hereunder or thereunder, and such
payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or preferential,
set aside, recovered from, disgorged by or are required to be refunded, repaid
or otherwise restored to the Company by a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the extent of any
such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.

         7.17     Adjustments in Share Numbers and Prices. In the event of any
stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder
thereof to receive directly or indirectly shares of Common Stock), combination
or other similar recapitalization or event occurring after the date hereof, each
reference in any Transaction Document to a number of shares or a price per share
shall be amended to appropriately account for such event.

                                       30

<PAGE>

         7.18     Independent Nature of Purchasers' Obligations and Rights. The
obligations of each Purchaser under any Transaction Document are several and not
joint with the obligations of any other Purchaser, and no Purchaser shall be
responsible in any way for the performance of the obligations of any other
Purchaser under any Transaction Document. The decision of each Purchaser to
purchase Shares pursuant to this Agreement has been made by such Purchaser
independently of any other Purchaser and independently of any information,
materials, statements or opinions as to the business, affairs, operations,
assets, properties, liabilities, results of operations, condition (financial or
otherwise) or prospects of the Company or of the Subsidiary which may have been
made or given by any other Purchaser or by any agent or employee of any other
Purchaser, and no Purchaser or any of its agents or employees shall have any
liability to any other Purchaser (or any other Person) relating to or arising
from any such information, materials, statements or opinions. Nothing contained
herein or in any Transaction Document, and no action taken by any Purchaser
pursuant thereto, shall be deemed to constitute the Purchasers as a partnership,
an association, a joint venture or any other kind of entity, or create a
presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the
Transaction Document. Each Purchaser acknowledges that no other Purchaser has
acted as agent for such Purchaser in connection with making its investment
hereunder and that no other Purchaser will be acting as agent of such Purchaser
in connection with monitoring its investment hereunder. Each Purchaser shall be
entitled to independently protect and enforce its rights, including without
limitation the rights arising out of this Agreement or out of the other
Transaction Documents, and it shall not be necessary for any other Purchaser to
be joined as an additional party in any proceeding for such purpose.

                           [SIGNATURE PAGES TO FOLLOW]

                                       31
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Securities
Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

                                    LYNX THERAPEUTICS, INC.

                                    By:    /s/ Kevin P. Corcoran
                                           -------------------------------------
                                    Name:  Kevin P. Corcoran
                                    Title: President and Chief Executive Officer

                                    Address for Notice:

                                    25861 Industrial Blvd.
                                    Hayward, CA  94545
                                    Facsimile No.:
                                    Telephone No.:
                                    Attn:

         With a copy to:            Cooley Godward LLP
                                    Five Palo Alto Square
                                    3000 El Camino Real
                                    Palo Alto, CA 94306-2155
                                    Facsimile No.: (650) 849-7400
                                    Telephone No.: (650) 843-5027
                                    Attn: James C. Kitch, Esq.

Consented and Acknowledged
with respect to Section 2.2(c) only

COOLEY GODWARD LLP

By:    /s/ James C. Kitch
       ------------------------
Name:  James C. Kitch
Title: Partner

                   [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
                     SIGNATURE PAGES FOR PURCHASERS FOLLOW]

<PAGE>

                                    VERTICAL VENTURES, LLC

                                    By:    /s/ Joshua Silverman
                                           -------------------------------------
                                    Name:  Joshua Silverman
                                    Title: Partner

                                    Purchase Price: $787,096.76

                                    Number of Shares to be acquired: 195,200

                                    Underlying Shares subject to Warrant: 48,800

                                    Address for Notice:

                                    Vertical Ventures, LLC
                                    641 Lexington Avenue, 26th Floor
                                    New York, NY 10022
                                    Facsimile No.: (212) 207-3452
                                    Telephone No.: (212) 974-3070
                                    Attn: Joshua Silverman

         With a copy to:            Proskauer Rose LLP
                                    1585 Broadway
                                    New York, New York  10036-8299
                                    Facsimile No.: (212) 969-2900
                                    Telephone No.: (212) 969-3000
                                    Attn:  Adam J. Kansler, Esq.

<PAGE>

                                    CLEVELAND OVERSEAS LIMITED

                                    By:    /s/ Ewald Vogt
                                           ------------------------------------
                                    Name:  Ewald Vogt
                                    Title:

                                    Purchase Price: $806,451.60

                                    Number of Shares to be acquired: 200,000

                                    Underlying Shares subject to Warrant: 50,000

                                    Address for Notice:

                                    c/o Vertical Ventures, LLC
                                    641 Lexington Avenue, 26th Floor
                                    New York, NY 10022
                                    Facsimile No.: (212) 207-3452
                                    Telephone No.: (212) 974-3070
                                    Attn: Joshua Silverman

<PAGE>

                                    XMARK FUND, L.P.

                                    By:    /s/ Mitchell Kaye
                                           -------------------------------------
                                    Name:  Mitchell Kaye
                                    Title:

                                    Purchase Price: $144,318.55

                                    Number of Shares to be acquired: 35,791

                                    Underlying Shares subject to Warrant: 8,950

                                    Address for Notice:

                                    Xmark Fund, L.P.
                                    152 West 57th Street, 21st Floor
                                    New York, New York  10019
                                    Facsimile No.: (212) 247-1329
                                    Telephone No.: (212) 247-8200
                                    Attn: Mitchell Kaye

<PAGE>

                                    XMARK FUNDS, LTD.

                                    By:    /s/ Mitchell Kaye
                                           -------------------------------------
                                    Name:  Mitchell Kaye
                                    Title:

                                    Purchase Price: $255,681.45

                                    Number of Shares to be acquired: 63,409

                                    Underlying Shares subject to Warrant: 15,850

                                    Address for Notice:

                                    Xmark Fund, Ltd.
                                    152 West 57th Street, 21st Floor
                                    New York, New York 10019
                                    Facsimile No.: (212) 247-1329
                                    Telephone No.: (212) 247-8200
                                    Attn: Mitchell Kaye

<PAGE>

                                    BONANZA MASTER FUND LTD.

                                    By:    /s/ Brian Laden
                                           -------------------------------------
                                    Name:  Brian Laden
                                    Title: Managing Director

                                    Purchase Price: $199,999.99

                                    Number of Shares to be acquired: 49,600

                                    Underlying Shares subject to Warrant: 12,400

                                    Address for Notice:

                                    8235 Douglas Ave., Suite 423

                                    Dallas, Tx 75225.

                                    Facsimile No.: 214.987.4342
                                    Telephone No.: 214.615.7090
                                    Attn: Brian Laden

<PAGE>

                                    CRANSHIRE CAPITAL, L.P.

                                    By:    /s/ Mitchell P. Kopin
                                           -------------------------------------
                                    Name:  Mitchell P. Kopin
                                    Title: President, Downview Capital,
                                            The General Partner

                                    Purchase Price: $ 806,451.60

                                    Number of Shares to be acquired:     200,000

                                    Underlying Shares subject to Warrant: 50,000

                                    Address for Notice:

                                    666 Dundee Raod, Suite 1901
                                    Northbrook, IL  60062
                                     Facsimile No.: 847-562-9031
                                    Telephone No.: 847-562-9030
                                    Attn: Mitchell P. Kopin

<PAGE>

         Exhibits:

A        Form of Warrant
B        Opinion of Company Counsel
C        Plan of Distribution
D        Transfer Agent Instructions

<PAGE>

                                    Exhibit A

                                [Form of Warrant]

   [The Form of Warrant is filed separately as Exhibit 10.40 of the Company's
           Current Report on Form 8-K, filed on September 25, 2003.]
<PAGE>

                                    Exhibit B

                           Opinion of Company Counsel

September __, 2003

To the Purchasers listed on Exhibit A hereto

RE: LYNX THERAPEUTICS, INC. PRIVATE PLACEMENT

Ladies and Gentlemen:

We have acted as counsel for Lynx Therapeutics, Inc., a Delaware corporation
(the "Company"), in connection with the issuance and sale of an aggregate of
seven hundred forty four thousand (744,000) shares (the "Shares") of the
Company's common stock, par value $.01 per share (the "Common Stock") and
warrants (the "Warrants") to purchase an aggregate of one hundred eighty six
thousand (186,000) shares of Common Stock (the "Warrant Shares") under the
Securities Purchase Agreement of even date herewith (the "Purchase Agreement"),
among the Company and the Purchasers named therein (the "Purchasers"). The
Shares, the Warrants and the Warrant Shares are collectively referred to herein
as the "Securities". We are rendering this opinion pursuant to Section 2.2 of
the Purchase Agreement. Except as otherwise defined herein, capitalized terms
used but not defined herein have the respective meanings given to them in the
Purchase Agreement.

In connection with this opinion, we have examined and relied upon the
representations and warranties as to factual matters contained in, and made
pursuant to, the Purchase Agreement by the various parties thereto, and have
examined and relied upon the originals or copies of such records, documents,
certificates, opinions, memoranda and other instruments as in our judgment are
necessary or appropriate to enable us to render the opinions expressed below.

As to certain factual matters, we have relied upon a certificate executed by an
officer of the Company, a copy of which has been provided to your counsel, and
have not sought to independently verify such matters. Where we render an opinion
"to the best of our knowledge" or concerning an item "known to us" or our
opinion otherwise refers to our knowledge, it is based solely upon (i) an
inquiry of attorneys within this firm who perform legal services for the
Company; (ii) a review of certificates executed by an officer of the Company
covering such matters; and (iii) such other investigation, if any, that we
specifically set forth herein.

With regard to our opinions in paragraph 5 and 6 below, insofar as they address
"to our knowledge" agreements of the Company, we have relied on a certificate
executed by an officer of the Company and have reviewed (i) the Company's
Amended and Restated Certificate of Incorporation, (ii) the Company's Bylaws, as
amended, (iii) any material contract to which the Company is a party and
attached as an exhibit to an SEC Report, and (iv) such other agreements, if any,
as are identified in such officer's certificate.

With regard to our opinions in paragraphs 8 and 9 with respect to the Warrant
Shares, we have assumed with your permission that the Warrant Shares are issued
upon exercise of the Warrants at

<PAGE>

the Closing and prior to the occurrence of any change in law or factual
circumstance that might affect the opinions expressed therein.

In rendering this opinion, we have assumed: the genuineness and authenticity of
all signatures on original documents; the authenticity of all documents
submitted to us as originals; the conformity to originals of all documents
submitted to us as copies; the accuracy, completeness and authenticity of
certificates of public officials; and the due authorization, execution and
delivery of all documents (except the due authorization, execution and delivery
by the Company of the Purchase Agreement and the Warrants (together, the
"Transaction Documents")) where authorization, execution and delivery are
prerequisites to the effectiveness of such documents. We have also assumed: that
all individuals executing and delivering documents in their individual
capacities had the legal capacity to so execute and deliver; that the
Transaction Documents are obligations binding upon the parties thereto other
than the Company; that the parties thereto other than the Company have received
all documents that they were to receive under the Transaction Documents; that
the parties to the Transaction Documents other than the Company have filed any
required California franchise tax or income tax returns and have paid any
required California franchise or income taxes; and that there are no extrinsic
agreements or understandings among the parties to the Transaction Documents that
would modify or interpret the terms thereof or the respective rights or
obligations of the parties thereunder.

Our opinions are expressed with respect only to the laws of the State of
California, the General Corporation Law of the State of Delaware and applicable
federal laws of the United States and are expressed only as to the outcome that
would pertain were California law, the General Corporation Law of the State of
Delaware or the federal laws of the United States (excluding choice of law
principles and excluding the effect of any law other than California law, the
General Corporation Law of the State of Delaware or the federal laws of the
United States) the governing law applicable to the relevant issue. We express no
opinion as to whether the laws of any particular jurisdiction apply. We note
that the parties to the Transaction Documents have designated the laws of the
State of New York as the laws governing such Transaction Documents. Accordingly,
with your permission, our opinion in paragraph 3 below as to the validity,
binding effect and enforceability of the Transaction Documents, is premised upon
the result that would obtain if a California court were to apply the internal
laws of the State of California (notwithstanding the designation of the laws of
the State of New York to govern the interpretation and enforcement of the
Transaction Documents). Neither special rulings of any governmental authorities
nor opinions of counsel in said jurisdiction have been obtained. We are not
rendering any opinion as to compliance with any federal or state (i) law, rule
or regulation relating to antitrust matters, or (ii) antifraud law, rule or
regulation relating to securities, or to the sale or issuance thereof or as to
the enforceability of any waiver of trial by jury.

With regard to our opinion in paragraph 1 below, with respect to the good
standing of the Company, we have relied solely on an examination of a
certificate of good standing issued by the Secretary of State of the State of
Delaware, dated September __, 2003 and a certificate of good standing issued by
the Secretary of State of the State of California, dated September __, 2003, and
a bringdown letter dated as of September __, 2003.

On the basis of the foregoing, in reliance thereon and with the foregoing
qualifications, we are of the opinion that:

<PAGE>

1.       The Company is a corporation duly incorporated, validly existing and in
         corporate good standing under the laws of the State of Delaware. The
         Company is duly qualified to do business as a foreign corporation and
         is in good standing under the laws of the state of California. The
         Company has the corporate power and authority to own and hold its
         properties and to carry on its business as currently conducted.

2.       The Company has the corporate power and authority to enter into,
         deliver and perform each of the Transaction Documents to which it is a
         party and to issue, sell and deliver the Shares and the Warrants, and
         to issue and deliver the Warrant Shares upon exercise of the Warrants.

3.       All necessary corporate action has been taken by the Company to
         authorize the execution, delivery and performance by the Company of
         each of the Transaction Documents to which it is a party. Each of the
         Transaction Documents has been duly executed and delivered by the
         Company and constitutes a valid and binding agreement of the Company
         enforceable against the Company in accordance with its terms, except as
         liquidated damages or penalty provisions and rights to indemnity and
         contribution may be limited by applicable laws and except as
         enforcement may be limited by applicable bankruptcy, insolvency,
         reorganization, arrangement, moratorium or other similar laws affecting
         creditors' rights, and subject to general equity principles and to
         limitations on availability of equitable relief, including specific
         performance.

4.       The execution and delivery by the Company of the Transaction Documents
         to which it is a party and the performance by it of its obligations
         thereunder will not (i) violate the General Corporation Law of the
         State of Delaware or federal law, or any court order, judgment or
         decree applicable to the Company and known to us, (ii) conflict with,
         result in a violation of or constitute a default under or breach of, or
         result in the creation of a lien or a right of acceleration under, any
         material contract to which the Company is a party and attached as an
         exhibit to an SEC Report or (iii) violate its Amended and Restated
         Certificate of Incorporation or Bylaws, as amended.

5.       The authorized capital stock of the Company immediately prior to the
         Closing consists of 60,000,000 shares of Common Stock, par value $0.01
         per share, of which, to our knowledge, 4,655,245 shares are validly
         issued and outstanding, fully paid and non-assessable, and 2,000,000
         shares of Preferred Stock, par value $0.01 per share, none of which are
         issued or outstanding. Except as set forth in the SEC Reports, the
         Transaction Documents, the Disclosure Schedule or the Company's Amended
         and Restated Certificate of Incorporation, to our knowledge, (i) no
         subscription, warrant, option, convertible security or other right to
         purchase or otherwise acquire shares of the capital stock or other
         equity securities of the Company under any agreement to which the
         Company is a party is authorized or outstanding and (ii) there is no
         commitment by the Company to issue shares, subscriptions, warrants,
         options, convertible securities or other such rights or to distribute
         to holders of any of its equity securities any evidence of indebtedness
         or asset. Except as provided in the Company's Amended and Restated
         Certificate of Incorporation, the SEC Reports, the Transaction
         Documents or the Disclosure Schedule, to our knowledge, (i) the Company
         has no obligation to purchase, redeem or otherwise acquire any of its
         equity securities or any interest therein or to pay any dividend or
         make any other distribution in respect thereof, and (ii) there are no
         voting trusts or agreements, stockholders' agreements, pledge
         agreements,

<PAGE>

         buy-sell agreements, rights of first refusal, preemptive rights,
         registration rights or proxies relating to any securities of the
         Company under any agreements to which the Company is a party.

6.       The Shares and the Warrant Shares have been duly authorized and the
         Warrant Shares have been reserved for issuance upon exercise of the
         Warrants. The issuance, sale and delivery of the Shares and the
         Warrants by the Company to the Purchasers in accordance with the
         Purchase Agreement, and the issuance and delivery of the Warrant Shares
         upon exercise of the Warrants, have been duly authorized by all
         necessary corporate action on the part of the Company. The Shares, when
         issued, sold and delivered against payment therefor in accordance with
         the provisions of the Purchase Agreement and the Warrant Shares, when
         issued upon exercise of the Warrants and payment therefor in accordance
         with the terms of the Warrants, will be duly and validly issued, fully
         paid and non-assessable. Except as set forth in the Transaction
         Documents or the Disclosure Schedule or the SEC Reports, neither the
         issuance, sale and delivery of the Shares and the Warrants nor the
         issuance and delivery of the Warrant Shares upon exercise of the
         Warrants is subject to any preemptive right or right of first refusal
         on the part of the holders of any class of securities of the Company
         arising under law, the Company's Amended and Restated Certificate of
         Incorporation or Bylaws, as amended, or, to our knowledge, under any
         other agreement to which the Company is a party.

7.       To our knowledge, no action, suit, claim or proceeding to which the
         Company or its subsidiaries is a party is pending or is overtly
         threatened in writing against the Company or its subsidiaries that
         could have a Material Adverse Effect or that questions the validity or
         enforceability of, or seeks to enjoin the performance of, the
         Transaction Documents.

8.       No notices, reports or other filings are required to be made by the
         Company or any of its subsidiaries with, nor are any consents,
         registrations, applications, approvals, permits, licenses or
         authorizations required to be obtained by the Company or any of its
         subsidiaries from any regulatory authority or governmental body in the
         United States required in connection with the consummation or
         performance by the Company of the transactions contemplated by the
         Transaction Documents or in connection with the issuance of the Shares
         and the Warrants or upon issuance of the Warrant Shares other than
         those contemplated by the Purchase Agreement and normal post-closing
         filings in connection with qualifying for exemptions from the
         registration requirements of applicable securities laws.

9.       Assuming the accuracy of the representations and warrants of the
         Company set forth in Section 3.1 of the Purchase Agreement and of the
         Purchasers set forth in Section 3.2 of the Purchase Agreement, the
         offer and sale of the Shares and Warrants pursuant to the Purchase
         Agreement is exempt from the registration requirements of the
         Securities Act subject to the timely filing of a Form D pursuant to
         Securities and Exchange Commission Regulation D.

10.      To our knowledge, the Company meets the eligibility requirements for
         the use of Form S-3 for the registration of the secondary offering of
         the Securities and Underlying Securities.

Our opinions are limited to the specific issues addressed and are limited in all
respects to laws and facts existing on the date hereof. By rendering our
opinions, we do not undertake to advise

<PAGE>

you of any changes in such laws or facts which may occur after the date hereof
or the effect that such changes or occurrences might have on our opinions.

Our opinions are limited to the matters expressly stated herein and are rendered
solely for your benefit and may not be quoted or relied upon for any other
purpose or by any other person, firm or entity without our prior written
consent.

Sincerely,

James C. Kitch

<PAGE>

                                    EXHIBIT C

                              PLAN OF DISTRIBUTION

         The selling stockholders may, from time to time, sell any or all of
their shares of common stock on any stock exchange, market or trading facility
on which the shares are traded or in private transactions. These sales may be at
fixed or negotiated prices. The selling stockholders may use any one or more of
the following methods when selling shares:

-        ordinary brokerage transactions and transactions in which the
         broker-dealer solicits purchasers;

-        block trades in which the broker-dealer will attempt to sell the shares
         as agent but may position and resell a portion of the block as
         principal to facilitate the transaction;

-        purchases by a broker-dealer as principal and resale by the
         broker-dealer for its account;

-        an exchange distribution in accordance with the rules of the applicable
         exchange;

-        privately negotiated transactions;

-        short sales;

-        broker-dealers may agree with the selling stockholders to sell a
         specified number of such shares at a stipulated price per share;

-        a combination of any such methods of sale; and

-        any other method permitted pursuant to applicable law.

         The selling stockholders may also sell shares under Rule 144 under the
Securities Act, if available, rather than under this prospectus.

         The selling stockholders may also engage in short sales against the
box, puts and calls and other transactions in our securities or derivatives of
our securities and may sell or deliver shares in connection with these trades.

         Broker-dealers engaged by the selling stockholders may arrange for
other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling stockholders (or, if any broker-dealer
acts as agent for the purchaser of shares, from the purchaser) in amounts to be
negotiated. The selling stockholders do not expect these commissions and
discounts to exceed what is customary in the types of transactions involved. Any
profits on the resale of shares of common stock by a broker-dealer acting as
principal might be deemed to be underwriting discounts or commissions under the
Securities Act. Discounts,

<PAGE>

concessions, commissions and similar selling expenses, if any, attributable to
the sale of shares will be borne by a selling stockholder. The selling
stockholders may agree to indemnify any agent, dealer or broker-dealer that
participates in transactions involving sales of the shares if liabilities are
imposed on that person under the Securities Act.

         The selling stockholders may from time to time pledge or grant a
security interest in some or all of the shares of common stock owned by them
and, if they default in the performance of their secured obligations, the
pledgees or secured parties may offer and sell the shares of common stock from
time to time under this prospectus after we have filed an amendment to this
prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act of 1933 amending the list of selling stockholders to include the pledgee,
transferee or other successors in interest as selling stockholders under this
prospectus.

         The selling stockholders also may transfer the shares of common stock
in other circumstances, in which case the transferees, pledgees or other
successors in interest will be the selling beneficial owners for purposes of
this prospectus and may sell the shares of common stock from time to time under
this prospectus after we have filed an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act of 1933 amending
the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus.

         The selling stockholders and any broker-dealers or agents that are
involved in selling the shares of common stock may be deemed to be
"underwriters" within the meaning of the Securities Act in connection with such
sales. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the shares of common stock purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act.

         We are required to pay all fees and expenses incident to the
registration of the shares of common stock, including $10,000 of fees and
disbursements of counsel to the selling stockholders. We have agreed to
indemnify the selling stockholders against certain losses, claims, damages and
liabilities, including liabilities under the Securities Act.

         The selling stockholders have advised us that they have not entered
into any agreements, understandings or arrangements with any underwriters or
broker-dealers regarding the sale of their shares of common stock, nor is there
an underwriter or coordinating broker acting in connection with a proposed sale
of shares of common stock by any selling stockholder. If we are notified by any
selling stockholder that any material arrangement has been entered into with a
broker-dealer for the sale of shares of common stock, if required, we will file
a supplement to this prospectus. If the selling stockholders use this prospectus
for any sale of the shares of common stock, they will be subject to the
prospectus delivery requirements of the Securities Act.

         The anti-manipulation rules of Regulation M under the Securities
Exchange Act of 1934 may apply to sales of our common stock and activities of
the selling stockholders.

<PAGE>

                                    Exhibit D

                     IRREVOCABLE TRANSFER AGENT INSTRUCTIONS

                             LYNX THERAPEUTICS, INC.

EquiServe Trust Company, N.A.

Ladies and Gentlemen:

Reference is made to the Securities Purchase Agreements (the "Purchase
Agreement"), dated as of September __ 2003, among Lynx Therapeutics, Inc., a
Delaware corporation (the "Company") and the purchasers named therein (the
"Holders") pursuant to which the Company is issuing the Company's common stock,
$0.01 par value per share (the "Common Stock"), and certain Common Stock
purchase warrants (the "Warrants") which shall be exercisable into shares of
Common Stock. The shares of Common Stock issued and transferred at the Closing
and issuable and transferable upon exercise of the Warrants are collectively
referred to herein as "Underlying Shares."

The Company has agreed with the Holders that it will instruct you to: (A) issue
the Underlying Shares free of all restrictive and other legends if, at the time
of such issue, (i) (a) a Holder has sold such Underlying Shares pursuant to a
then-effective registration statement covering the resale of such Underlying
Shares and (b) such Holder represents that the prospectus delivery requirements
of the Securities Act have been met, (ii) such Underlying Shares are eligible
for sale under Rule 144(k) or (iii) such legend is not required under applicable
requirements of the Securities Act (including judicial interpretations and
pronouncements issued by the Staff of the Commission); or (B) reissue the
Underlying Shares (if such shares were originally issued with a restrictive
legend) free of all restrictive and other legends (i) a Holder has sold such
Underlying Shares pursuant to a then-effective registration statement covering
the resale of such Underlying Shares or (ii) following any sale of such
Underlying Shares pursuant to Rule 144 or (iii) such Underlying Shares are
eligible for sale under Rule 144(k) or (iv) if such legend is not required under
applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the Staff of the Commission).

Pursuant to the foregoing, either the Company or our counsel will prepare
further letters in order to effect any future issuance or reissuance of shares
of Common Stock to the Holders as contemplated by the Purchase Agreement and
this letter. This letter shall serve as our standing irrevocable instructions
with regard to this matter

Please be advised that the Holders have relied upon this instruction letter as
an inducement to enter into the Purchase Agreement. Please execute this letter
in the space indicated to acknowledge your agreement to act in accordance with
these instructions.

                                            Very truly yours,

<PAGE>

                                                     LYNX THERAPEUTICS, INC.

                                                     By: _______________________
                                                     Name: _____________________
                                                     Title: ____________________

ACKNOWLEDGED AND AGREED:

EquiServe Trust Company, N.A.

By: _______________________________
Name: _____________________________
Title: ____________________________<PAGE>

                                                                   EXHIBIT 10.40

                                    EXHIBIT A

NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE
SECURITIES OR BLUE SKY LAWS. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

                            LYNX THERAPEUTICS, INC.

                                     WARRANT

Warrant No. [ ]                                        Dated: September __, 2003

         Lynx Therapeutics, Inc., a Delaware corporation (the "COMPANY"), hereby
certifies that, for value received, [Name of Holder] or its registered assigns
(the "HOLDER"), is entitled to purchase from the Company up to a total of [ ]1
shares of common stock, $0.01 par value per share (the "COMMON STOCK"), of the
Company (each such share, a "WARRANT SHARE" and all such shares, the "WARRANT
SHARES") at an exercise price equal to $9.91 per share (as adjusted from time to
time as provided in Section 9, the "EXERCISE PRICE"), at any time and from time
to time from and after the date hereof and through and including the date that
is five years from the date of issuance hereof (the "EXPIRATION DATE"), and
subject to the following terms and conditions. This Warrant (this "WARRANT") is
one of a series of similar warrants issued pursuant to that certain Securities
Purchase Agreement, dated as of the date hereof, by and among the Company and
the Purchasers identified therein (the "PURCHASE AGREEMENT"). All such warrants
are referred to herein, collectively, as the "WARRANTS."

         1.       Definitions. In addition to the terms defined elsewhere in
this Warrant, capitalized terms that are not otherwise defined herein have the
meanings given to such terms in the Purchase Agreement.

         2.       Registration of Warrant. The Company shall register this
Warrant, upon records to be maintained by the Company for that purpose (the
"WARRANT REGISTER"), in the name of the record Holder hereof from time to time.
The Company may deem and treat the registered Holder

--------------------
(1) 25% warrant coverage

<PAGE>

of this Warrant as the absolute owner hereof for the purpose of any exercise
hereof or any distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.

         3.       Registration of Transfers. The Company shall register the
transfer of any portion of this Warrant in the Warrant Register, upon surrender
of this Warrant, with the Form of Assignment attached hereto duly completed and
signed, to the Transfer Agent or to the Company at its address specified herein.
Upon any such registration or transfer, a new warrant to purchase Common Stock,
in substantially the form of this Warrant (any such new warrant, a "NEW
WARRANT"), evidencing the portion of this Warrant so transferred shall be issued
to the transferee and a New Warrant evidencing the remaining portion of this
Warrant not so transferred, if any, shall be issued to the transferring Holder.
The acceptance of the New Warrant by the transferee thereof shall be deemed the
acceptance by such transferee of all of the rights and obligations of a holder
of a Warrant.

         4.       Exercise and Duration of Warrants.

                  (a)      This Warrant shall be exercisable by the registered
Holder at any time and from time to time on or after the date hereof to and
including the Expiration Date. At 6:30 P.M., New York City time on the
Expiration Date, the portion of this Warrant not exercised prior thereto shall
be and become void and of no value; provided that, if the average of the Closing
Prices for the five Trading Days immediately prior to (but not including) the
Expiration Date exceeds the Exercise Price on the Expiration Date, then this
Warrant shall be deemed to have been exercised in full (to the extent not
previously exercised) on a "cashless exercise" basis at 6:30 P.M. New York City
time on the Expiration Date if a "cashless exercise" may occur at such time
pursuant to Section 10 below.

                  (b)      A Holder may exercise this Warrant by delivering to
the Company (i) an exercise notice, in the form attached hereto (the "EXERCISE
NOTICE"), appropriately completed and duly signed, and (ii) payment of the
Exercise Price for the number of Warrant Shares as to which this Warrant is
being exercised (which may take the form of a "cashless exercise" if so
indicated in the Exercise Notice and if a "cashless exercise" may occur at such
time pursuant to this Section 10 below), and the date such items are delivered
to the Company (as determined in accordance with the notice provisions hereof)
is an "EXERCISE DATE." The Holder shall not be required to deliver the original
Warrant in order to effect an exercise hereunder. Execution and delivery of the
Exercise Notice shall have the same effect as cancellation of the original
Warrant and issuance of a New Warrant evidencing the right to purchase the
remaining number of Warrant Shares.

         5.       Delivery of Warrant Shares.

                  (a)      Upon exercise of this Warrant, the Company shall
promptly (but in no event later than three Trading Days after the Exercise Date)
issue or cause to be issued and cause to be delivered to or upon the written
order of the Holder and in such name or names as the Holder may designate, a
certificate for the Warrant Shares issuable upon such exercise. The Holder, or
any Person so designated by the Holder to receive Warrant Shares, shall be
deemed to have become holder of record of such Warrant Shares as of the Exercise
Date. The Company shall, upon request of the Holder, use its best efforts to
deliver Warrant Shares hereunder

                                       2
<PAGE>

electronically through the Depository Trust Corporation or another established
clearing corporation performing similar functions.

                  (b)      This Warrant is exercisable, either in its entirety
or, from time to time, for a portion of the number of Warrant Shares. Upon
surrender of this Warrant following one or more partial exercises, the Company
shall issue or cause to be issued, at its expense, a New Warrant evidencing the
right to purchase the remaining number of Warrant Shares.

                  (c)      The Company's obligations to issue and deliver
Warrant Shares in accordance with the terms hereof are absolute and
unconditional, irrespective of any action or inaction by the Holder to enforce
the same, any waiver or consent with respect to any provision hereof, the
recovery of any judgment against any Person or any action to enforce the same,
or any setoff, counterclaim, recoupment, limitation or termination, or any
breach or alleged breach by the Holder or any other Person of any obligation to
the Company or any violation or alleged violation of law by the Holder or any
other Person, and irrespective of any other circumstance which might otherwise
limit such obligation of the Company to the Holder in connection with the
issuance of Warrant Shares. Nothing herein shall limit a Holder's right to
pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company's failure to timely deliver
certificates representing shares of Common Stock upon exercise of the Warrant as
required pursuant to the terms hereof.

         6.       Charges, Taxes and Expenses. Issuance and delivery of
certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, withholding
tax, transfer agent fee or other incidental tax or expense in respect of the
issuance of such certificates, all of which taxes and expenses shall be paid by
the Company; provided, however, that the Company shall not be required to pay
any tax which may be payable in respect of any transfer involved in the
registration of any certificates for Warrant Shares or Warrants in a name other
than that of the Holder or an Affiliate thereof. The Holder shall be responsible
for all other tax liability that may arise as a result of holding or
transferring this Warrant or receiving Warrant Shares upon exercise hereof.

         7.       Replacement of Warrant. If this Warrant is mutilated, lost,
stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and
substitution for this Warrant, a New Warrant, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction and
customary and reasonable indemnity, if requested. Applicants for a New Warrant
under such circumstances shall also comply with such other reasonable
regulations and procedures and pay such other reasonable third-party costs as
the Company may prescribe.

         8.       Reservation of Warrant Shares. The Company covenants that it
will at all times reserve and keep available out of the aggregate of its
authorized but unissued and otherwise unreserved Common Stock, solely for the
purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares which are then issuable and
deliverable upon the exercise of this entire Warrant, free from preemptive
rights or any other contingent purchase rights of persons other than the Holder
(taking into account the adjustments and restrictions of Section 9). The Company
covenants that all Warrant Shares so

                                       3
<PAGE>

issuable and deliverable shall, upon issuance and the payment of the applicable
Exercise Price in accordance with the terms hereof, be duly and validly
authorized, issued and fully paid and nonassessable. The Company will take all
such action as may be necessary to assure that such shares of Common Stock may
be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated
quotation system upon which the Common Stock may be listed.

         9.       Certain Adjustments. The Exercise Price and number of Warrant
Shares issuable upon exercise of this Warrant are subject to adjustment from
time to time as set forth in this Section 9.

                  (a)      Stock Dividends and Splits. If the Company, at any
time while this Warrant is outstanding, (i) pays a stock dividend on its Common
Stock or otherwise makes a distribution on any class of capital stock that is
payable in shares of Common Stock, (ii) subdivides outstanding shares of Common
Stock into a larger number of shares, or (iii) combines outstanding shares of
Common Stock into a smaller number of shares, then in each such case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event. Any adjustment made pursuant to clause
(i) of this paragraph shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or
distribution, and any adjustment pursuant to clause (ii) or (iii) of this
paragraph shall become effective immediately after the effective date of such
subdivision or combination. Simultaneously with any adjustment to the Exercise
Price pursuant to this paragraph (a) of Section, the number of Warrant Shares
that may be purchased upon exercise of this Warrant shall be increased or
decreased proportionately, so that after such adjustment the aggregate Exercise
Price payable hereunder for the increased or decreased number of Warrant Shares
shall be the same as the aggregate Exercise Price in effect immediately prior to
such adjustment.

                  (b)      Pro Rata Distributions. If the Company, at any time
while this Warrant is outstanding, distributes to holders of Common Stock (i)
evidences of its indebtedness, (ii) any security (other than a distribution of
Common Stock covered by the preceding paragraph), (iii) rights or warrants to
subscribe for or purchase any security, or (iv) any other asset (in each case,
"DISTRIBUTED PROPERTY"), then in each such case the Exercise Price in effect
immediately prior to the record date fixed for determination of stockholders
entitled to receive such distribution shall be adjusted (effective on such
record date) to equal the product of such Exercise Price times a fraction of
which the denominator shall be the average of the Closing Prices for the five
Trading Days immediately prior to (but not including) such record date and of
which the numerator shall be such average less the then fair market value of the
Distributed Property distributed in respect of one outstanding share of Common
Stock, as determined by the Company's independent certified public accountants
that regularly examine the financial statements of the Company (an "APPRAISER").
In such event, the Holder, after receipt of the determination by the Appraiser,
shall have the right to select an additional appraiser (which shall be a
nationally recognized accounting firm), in which case such fair market value
shall be deemed to equal the average of the values determined by each of the
Appraiser and such appraiser.

                                       4
<PAGE>

                  (c)      Fundamental Transactions. If, at any time while this
Warrant is outstanding, (i) the Company effects any merger or consolidation of
the Company with or into another Person, (ii) the Company effects any sale of
all or substantially all of its assets in one or a series of related
transactions, (iii) any tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are
permitted to tender or exchange their shares for other securities, cash or
property, or (iv) the Company effects any reclassification of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property
(other than as a result of a subdivision or combination of shares of Common
Stock covered by Section 9(a) above) (in any such case, a "FUNDAMENTAL
TRANSACTION"), then the Holder shall have the right thereafter to receive, upon
exercise of this Warrant, the same amount and kind of securities, cash or
property as it would have been entitled to receive upon the occurrence of such
Fundamental Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the number of Warrant Shares then issuable upon
exercise in full of this Warrant (the "ALTERNATE CONSIDERATION"). The aggregate
Exercise Price for this Warrant will not be affected by any such Fundamental
Transaction, but the Company shall apportion such aggregate Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. At the Holder's request, any successor
to the Company or surviving entity in such Fundamental Transaction shall issue
to the Holder a new warrant consistent with the foregoing provisions and
evidencing the Holder's right to purchase the Alternate Consideration for the
aggregate Exercise Price upon exercise thereof. The terms of any agreement
pursuant to which a Fundamental Transaction is effected shall include terms
requiring any such successor or surviving entity to comply with the provisions
of this paragraph (c) and insuring that the Warrant (or any such replacement
security) will be similarly adjusted upon any subsequent transaction analogous
to a Fundamental Transaction. If any Fundamental Transaction constitutes or
results in a Change of Control, then at the request of the Holder delivered
before the 90th day after such Fundamental Transaction, the Company (or any such
successor or surviving entity) will purchase the Warrant from the Holder for a
purchase price, payable in cash within five Trading Days after such request (or,
if later, on the effective date of the Fundamental Transaction), equal to the
Black-Scholes value of the remaining unexercised portion of this Warrant on the
date of such request.

                  (d)      Subsequent Equity Sales.

                           (i)      If, at any time prior to the one year
         anniversary of the Closing Date, the Company or any Subsidiary issues
         additional shares of Common Stock or rights, warrants, options or other
         securities or debt convertible, exercisable or exchangeable for shares
         of Common Stock or otherwise entitling any Person to acquire shares of
         Common Stock (collectively, "COMMON STOCK EQUIVALENTS") at an effective
         net price to the Company per share of Common Stock (the "EFFECTIVE
         PRICE") less than the Exercise Price (as adjusted hereunder to such
         date), then the Exercise Price shall be reduced to equal the product of
         (A) the Exercise Price in effect immediately prior to such issuance of
         Common Stock or Common Stock Equivalents times (B) a fraction, the

                                       5
<PAGE>

         numerator of which is the sum of (1) the number of shares of Common
         Stock outstanding immediately prior to such issuance, plus (2) the
         number of shares of Common Stock which the aggregate Effective Price of
         the Common Stock issued (or deemed to be issued) would purchase at the
         Exercise Price, and the denominator of which is the aggregate number of
         shares of Common Stock outstanding or deemed to be outstanding
         immediately after such issuance. For purposes of this paragraph, in
         connection with any issuance of any Common Stock Equivalents, (A) the
         maximum number of shares of Common Stock potentially issuable at any
         time upon conversion, exercise or exchange of such Common Stock
         Equivalents (the "DEEMED NUMBER") shall be deemed to be outstanding
         upon issuance of such Common Stock Equivalents, (B) the Effective Price
         applicable to such Common Stock shall equal the minimum dollar value of
         consideration payable to the Company to purchase such Common Stock
         Equivalents and to convert, exercise or exchange them into Common Stock
         (net of any discounts, fees, commissions and other expenses), divided
         by the Deemed Number, and (C) no further adjustment shall be made to
         the Exercise Price upon the actual issuance of Common Stock upon
         conversion, exercise or exchange of such Common Stock Equivalents.

                           (ii)     If, at any time while this Warrant is
         outstanding, the Company or any Subsidiary issues Common Stock
         Equivalents with an Effective Price or a number of underlying shares
         that floats or resets or otherwise varies or is subject to adjustment
         based (directly or indirectly) on market prices of the Common Stock (a
         "FLOATING PRICE SECURITY"), then for purposes of applying the preceding
         paragraph in connection with any subsequent exercise, the Effective
         Price will be determined separately on each Exercise Date and will be
         deemed to equal the lowest Effective Price at which any holder of such
         Floating Price Security is entitled to acquire Common Stock on such
         Exercise Date (regardless of whether any such holder actually acquires
         any shares on such date).

                           (iii)    Notwithstanding the foregoing, no adjustment
         will be made under this paragraph (d) in respect to any issuance of
         Common Stock (A) upon exercise or conversion of any options or other
         securities described in Schedule 3.1(f) of the Purchase Agreement
         (provided that such exercise or conversion occurs in accordance with
         the terms thereof, without amendment or modification, and that the
         applicable exercise or conversion price or ratio is described in such
         schedule) or otherwise pursuant to any employee benefit plan described
         in Schedule 3.1(f) of the Purchase Agreement or hereafter adopted by
         the Company and approved by its stockholders, or (B) in connection with
         any grant of options to employees, officers, directors or consultants
         of the Company pursuant to a stock option plan duly adopted by the
         Company's board of directors or in respect of the issuance of Common
         Stock upon exercise of any such options.

                  (e)      Calculations. All calculations under this Section 9
shall be made to the nearest cent or the nearest 1/100th of a share, as
applicable. The number of shares of Common Stock outstanding at any given time
shall not include shares owned or held by or for the account of the Company, and
the disposition of any such shares shall be considered an issue or sale of
Common Stock.

                  (f)      Notice of Adjustments. Upon the occurrence of each
adjustment pursuant to this Section 9, the Company at its expense will promptly
compute such adjustment in

                                       6
<PAGE>

accordance with the terms of this Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and
adjusted number or type of Warrant Shares or other securities issuable upon
exercise of this Warrant (as applicable), describing the transactions giving
rise to such adjustments and showing in detail the facts upon which such
adjustment is based. Upon written request, the Company will promptly deliver a
copy of each such certificate to the Holder and to the Company's Transfer Agent.

                  (g)      Notice of Corporate Events. If the Company (i)
declares a dividend or any other distribution of cash, securities or other
property in respect of its Common Stock, including without limitation any
granting of rights or warrants to subscribe for or purchase any capital stock of
the Company, (ii) authorizes or approves, enters into any agreement
contemplating any Fundamental Transaction or (iii) authorizes the voluntary
dissolution, liquidation or winding up of the affairs of the Company, then the
Company shall deliver to the Holder a notice describing the material terms and
conditions of such transaction, at least 15 calendar days prior to the
applicable record or effective date on which a Person would need to hold Common
Stock in order to participate in such transaction, and the Company will take all
steps reasonably necessary in order to insure that the Holder is given the
practical opportunity to exercise this Warrant prior to such time so as to
participate in such transaction; provided, however, that the failure to deliver
such notice or any defect therein shall not affect the validity of the
transaction required to be described in such notice.

         10.      Payment of Exercise Price. The Holder shall pay the Exercise
Price in immediately available funds; provided, however, the Holder may satisfy
its obligation to pay the Exercise Price through a "cashless exercise," in which
event the Company shall issue to the Holder the number of Warrant Shares
determined as follows:

                           X = Y [(A-B)/A]
                  where:
                           X = the number of Warrant Shares to be issued to the
                           Holder.

                           Y = the number of Warrant Shares with respect to
                           which this Warrant is being exercised.

                           A = the average of the Closing Prices for the five
                           Trading Days immediately prior to (but not including)
                           the Exercise Date.

                           B = the Exercise Price.

                  For purposes of Rule 144 promulgated under the Securities Act,
it is intended, understood and acknowledged that the Warrant Shares issued in a
cashless exercise transaction shall be deemed to have been acquired by the
Holder, and the holding period for the Warrant Shares shall be deemed to have
commenced, on the date this Warrant was originally issued pursuant to the
Purchase Agreement.

         11.      Limitation on Exercise. Notwithstanding anything to the
contrary contained herein, the number of shares of Common Stock that may be
acquired by the Holder upon any

                                       7
<PAGE>

exercise of this Warrant (or otherwise in respect hereof) shall be limited to
the extent necessary to insure that, following such exercise (or other
issuance), the total number of shares of Common Stock then beneficially owned by
such Holder and its Affiliates and any other Persons whose beneficial ownership
of Common Stock would be aggregated with the Holder's for purposes of Section
13(d) of the Exchange Act, does not exceed 4.999% (the "MAXIMUM PERCENTAGE") of
the total number of issued and outstanding shares of Common Stock (including for
such purpose the shares of Common Stock issuable upon such exercise). For such
purposes, beneficial ownership shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
Each delivery of an Exercise Notice hereunder will constitute a representation
by the Holder that it has evaluated the limitation set forth in this paragraph
and determined that issuance of the full number of Warrant Shares requested in
such Exercise Notice is permitted under this paragraph. The Company's obligation
to issue shares of Common Stock in excess of the limitation referred to in this
Section shall be suspended (and shall not terminate or expire notwithstanding
any contrary provisions hereof) until such time, if any, as such shares of
Common Stock may be issued in compliance with such limitation. By written notice
to the Company, the Holder may waive the provisions of this Section or increase
or decrease the Maximum Percentage to any other percentage specified in such
notice, but (i) any such waiver or increase will not be effective until the 61st
day after such notice is delivered to the Company, and (ii) any such waiver or
increase or decrease will apply only to the Holder and not to any other holder
of Warrants.

         12.      Fractional Shares. The Company shall not be required to issue
or cause to be issued fractional Warrant Shares on the exercise of this Warrant.
If any fraction of a Warrant Share would, except for the provisions of this
Section, be issuable upon exercise of this Warrant, the number of Warrant Shares
to be issued will be rounded up to the nearest whole share.

         13.      Notices. Any and all notices or other communications or
deliveries hereunder (including without limitation any Exercise Notice) shall be
in writing and shall be deemed given and effective on the earliest of (i) the
date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number specified in this Section prior to 6:30 p.m. (New York
City time) on a Trading Day, (ii) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in this Section on a day that is not a Trading Day or
later than 6:30 p.m. (New York City time) on any Trading Day, (iii) the Trading
Day following the date of mailing, if sent by nationally recognized overnight
courier service, or (iv) upon actual receipt by the party to whom such notice is
required to be given. The address for such notices or communications shall be as
set forth in the Purchase Agreement.

         14.      Warrant Agent. The Company shall serve as warrant agent under
this Warrant. Upon 30 days' notice to the Holder, the Company may appoint a new
warrant agent. Any corporation into which the Company or any new warrant agent
may be merged or any corporation resulting from any consolidation to which the
Company or any new warrant agent shall be a party or any corporation to which
the Company or any new warrant agent transfers substantially all of its
corporate trust or stockholders services business shall be a successor warrant
agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be
mailed (by first class mail, postage prepaid) to the Holder at the Holder's last
address as shown on the Warrant Register.

                                       8
<PAGE>

         15.      Miscellaneous.

                  (a)      Subject to the restrictions on transfer set forth on
the first page hereof, this Warrant may be assigned by the Holder. This Warrant
may not be assigned by the Company except to a successor in the event of a
Fundamental Transaction. This Warrant shall be binding on and inure to the
benefit of the parties hereto and their respective successors and assigns.
Subject to the preceding sentence, nothing in this Warrant shall be construed to
give to any Person other than the Company and the Holder any legal or equitable
right, remedy or cause of action under this Warrant. This Warrant may be amended
only in writing signed by the Company and the Holder and their successors and
assigns.

                  (b)      The Company will not, by amendment of its governing
documents or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Holder against impairment.
Without limiting the generality of the foregoing, the Company (i) will not
increase the par value of any Warrant Shares above the amount payable therefor
on such exercise, (ii) will take all such action as may be reasonably necessary
or appropriate in order that the Company may validly and legally issue fully
paid and nonassessable Warrant Shares on the exercise of this Warrant, and (iii)
will not close its stockholder books or records in any manner which interferes
with the timely exercise of this Warrant.

                  (c)      GOVERNING LAW; VENUE; WAIVER OF JURY TRIAL. ALL
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION
OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF NEW YORK. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO
THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY
OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR
DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE
TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT
IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT
TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS
IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND
CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY
MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY
(WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES
TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD
AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN
SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER
PERMITTED BY LAW. THE COMPANY HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

                  (d)      The headings herein are for convenience only, do not
constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.

                                       9
<PAGE>

                  (e)      In case any one or more of the provisions of this
Warrant shall be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Warrant shall not
in any way be affected or impaired thereby and the parties will attempt in good
faith to agree upon a valid and enforceable provision which shall be a
commercially reasonable substitute therefor, and upon so agreeing, shall
incorporate such substitute provision in this Warrant.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,
                             SIGNATURE PAGE FOLLOWS]

                                       10
<PAGE>

         IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed by its authorized officer as of the date first indicated above.

                                            LYNX THERAPEUTICS, INC.

                                            By: ___________________________
                                            Name: _________________________
                                            Title: ________________________

                                       11
<PAGE>

                             FORM OF EXERCISE NOTICE

(To be executed by the Holder to exercise the right to purchase shares of Common
Stock under the foregoing Warrant)

To: LYNX THERAPEUTICS, INC.

The undersigned is the Holder of Warrant No. _______ (the "WARRANT") issued by
Lynx Therapeutics, Inc., a Delaware corporation (the "COMPANY"). Capitalized
terms used herein and not otherwise defined have the respective meanings set
forth in the Warrant.

1.       The Warrant is currently exercisable to purchase a total of
         ______________ Warrant Shares.

2.       The undersigned Holder hereby exercises its right to purchase
         _________________ Warrant Shares pursuant to the Warrant.

3.       The Holder intends that payment of the Exercise Price shall be made as
         (check one):

                    ____ "Cash Exercise" under Section 10

                    ____ "Cashless Exercise" under Section 10

4.       If the holder has elected a Cash Exercise, the holder shall pay the sum
         of $____________ to the Company in accordance with the terms of the
         Warrant.

5.       Pursuant to this exercise, the Company shall deliver to the holder
         _______________ Warrant Shares in accordance with the terms of the
         Warrant.

6.       Following this exercise, the Warrant shall be exercisable to purchase a
         total of ______________ Warrant Shares.

Dated: ____________,____                       Name of Holder:

                                               (Print)__________________________

                                               By: _____________________________
                                               Name: ___________________________
                                               Title: __________________________

                                               (Signature must conform in all
                                               respects to name of holder as
                                               specified on the face of the
                                               Warrant)

<PAGE>

                               FORM OF ASSIGNMENT

         [To be completed and signed only upon transfer of Warrant]

         FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto ________________________________ the right represented by the within
Warrant to purchase ____________ shares of Common Stock of Lynx Therapeutics,
Inc. to which the within Warrant relates and appoints ________________ attorney
to transfer said right on the books of Lynx Therapeutics, Inc. with full power
of substitution in the premises.

Dated: ____________,____

                                               _________________________________
                                               (Signature must conform in all
                                               respects to name of holder as
                                               specified on the face of the
                                               Warrant)

                                               _________________________________
                                               Address of Transferee

                                               _________________________________

                                               _________________________________

In the presence of:

_________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]